Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
07/2008 | Recent  |  08: Dec | Nov | Oct | Sp | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 07: D | N | O | S | A | J | J | M | A | M | F | J |  | 06: 12 | 11 | 10 | 09 | 8 | 7 | 6 | 5 | 4 | Dec | Nov |  | 2010 | 2009 |

Drug, bio-affecting and body treating compositions July cataloged by category listing 07/08

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
07/31/2008 > patent applications in patent subcategories. cataloged by category listing

20080182779 - Apelin and uses thereof: The invention provides a method of treating or preventing heart failure or a disease or condition associated with heart failure comprising administering an effective dose of an apelin peptide or APJ receptor ligand to the subject. According to certain embodiments of the invention the apelin peptide is administered chronically. In... Agent: Bozicevic, Field & Francis LLP

20080182776 - Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process foe the preparation thereof: A process for preparing the drug-loaded cyanoacrylate nanoparticles is described. The cyanoacrylate nanoparticles which effectively deliver biological and therapeutic agents are synthesized by miniemulsion polymerization with surfactant, pluronic F127 or F68. Before initiation of polymerization, active agents with particularly highly hydrophobicity are dissolved in cyanoacrylate monomer. Compared with the drug-loaded... Agent: Joe Mckinney Muncy

20080182778 - Identification of an evolutionarily conserved pathway mediating transrepression of inflammatory response genes by nuclear receptors: The present invention relates to a method of screening for a compound that regulate SUMOylation of the nuclear receptor proteins comprising contacting the compound of interest to the nuclear receptor protein, and detecting SUMOylation of the nuclear receptor protein, thereby screening for a compound that regulates SUMOylation.... Agent: Mandel & Adriano

20080182775 - Nonhuman animal reproducing pathogenic conditions of spinal and bulbar muscular atrophy and remedy for spinal and bulbar muscular atrophy: It is intended to provide a model animal faithfully reproducing the pathogenic conditions of spinal and bulbar muscular atrophy, a method of screening a remedy for polyglutamine disease using the same, and a remedy for spinal and bulbar muscular atrophy. Namely, a nonhuman animal having the following characteristics (1) to... Agent: Kratz, Quintos & Hanson, LLP

20080182777 - Regulation of cell migration and adhesion: Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis. MMPs are thought to be regulated by a variety of cytokines, growth factors, hormones and phorbol esters. This regulation occurs on three levels; alteration of gene... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080182780 - Method of preventing or reducing scarring of human skin: Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents... Agent: Sonnenschein Nath & Rosenthal LLP

20080182787 - Agent and compositions comprising the same for inhibiting lipases and phospholipases in body fluids, cells and tissues: The present invention deals with a protein and compositions comprising the same for inhibition of lipases and phospholipases in the body fluids, cells, and tissues for the prevention and treatment of metabolic syndrome, cardiovascular disorders, and inflammatory diseases. The protein is either isolated from plant species or synthesized or produced... Agent: Lackenbach Siegel, LLP

20080182790 - Bacterial strains, genes and enzymes for control of bacterial diseases by quenching quorum-sensing signals: The present invention relates to isolated nucleic acid molecules encoding an autoinducer inactivation protein, wherein the encoded protein comprises an amino acid sequence selected from the group consisting of 104HXHXDH109˜60aa˜H169˜21aa˜D191 and 103HXHXDH108˜72aa˜H180˜21aa˜D202, and to expression vectors and transformed plant and animal cells comprising the same. The proteins encoded by these... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080182793 - C-type lectin polypeptide, polynucleotide and methods of making and use thereof: Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides.... Agent: Immunex Corporation Law Department

20080182788 - Compositions and methods for increasing bone mineralization: A novel class or family of TGF-β binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.... Agent: Marshall, Gerstein & Borun LLP

20080182782 - Cytotoxic factors for modulating cell death: Cytotoxic factors having use in modulating cell death, and their use in methods of treating necrosis or apoptosis-related conditions are disclosed. The invention also relates to methods for identifying active agents useful in treating conditions related to cell death or uncontrolled growth. The present inventors have found that different microorganisms... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP Attn: Ellen Klann

20080182783 - Growth hormone conjugates: t

20080182791 - Medicament for improving prognostic survival in therapy of malignant tumor: A medicament for improving prognostic survival in therapy of malignant tumor is provided that may improve prognostic survival in DIC patients where the basal disease is malignant tumor, especially malignant tumor in hematopoietic organs. The medicament according to the invention comprises as a main active ingredient Activated Protein C, which... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080182789 - Method of treating pulmonary fibrosis: Methods and compositions for treating pulmonary fibrosis are presented. Methods comprise administering compositions comprising DNA and streptolysin O to a subject in a manner so as not to effect gene transfer.... Agent: Marshall, Gerstein & Borun LLP

20080182784 - Methods and compositions for treating neurological disorders: This disclosure relates to methods and compositions useful for the treatment of senile dementia. More particularly the disclosure relates to methods and compositions for the treatment of senile dementia related to diabetes.... Agent: Crowell & Moring LLP Intellectual Property Group

20080182792 - Neurodegenerative protein aggregation inhibition methods and compounds: Methods and compositions are provided for reducing aggregation of neurodegenerative proteins associated with neurotoxicity or other proteins. The compounds comprise a first domain or targeting element for binding to the target proteins linked to a second domain or recruiting element that binds to an aggregation inhibiting protein, e.g. a prolyl... Agent: Bozicevic, Field & Francis LLP

20080182785 - Protracted glp-1 compounds: Novel protracted GLP-1 compounds and therapeutic uses thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080182786 - Support for protein transfer, protein transfer agent using the support, protein transfer method, cell having protein transferred thereinto and method of producing the same: A protein introduction method with which protein can be introduced into cells with excellent safety is provided. A target protein is supported on a carrier for protein introduction that is made from a clay mineral, and by adding this to cells it is possible to introduce the target protein into... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080182794 - Methods for treating breast cancer using nrif3 related molecules: Disclosed herein is the discovery that administration of the NRIF3 family of transcriptional coregulators (NRIF3 and related molecules) to breast cancer cells induce rapid and profound apoptosis (nearly 100% cell death within 24 h). A novel death domain (DD1) was mapped to a short 30 amino acid region common to... Agent: Darby & Darby P.C.

20080182795 - Specific antagonists for glucose-depenent insulinotropic polypeptide (gip): In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of treating non-insulin dependent diabetes mellitus in a patient comprising administering to... Agent: Edwards Angell Palmer & Dodge LLP

20080182796 - Modified cry3a toxins and nucleic acid sequences coding therefor: Compositions and methods for controlling plant pests are disclosed. In particular, novel nucleic acid sequences encoding modified Cry3A toxins having increased toxicity to corn rootworm are provided. By inserting a protease recognition site that is recognized by a gut protease of a target insect in at least one position of... Agent: Syngenta Biotechnology, Inc. Patent Department

20080182797 - Short peptides useful for treatment of ischemia/reperfusion injury and other tissue damage conditions associated with nitric oxide and its reactive species: This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess... Agent: Darby & Darby P.C.

20080182798 - Novel effectors of dipeptidyl peptidase iv: Dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof used in the treatment of impaired glucose tolerance, glycosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and also of sequelae of diabetes mellitus in... Agent: Osi Pharmaceuticals, Inc.

20080182799 - Botulinum toxin screening assays: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.... Agent: Allergan, Inc.

20080182800 - Composition for preventing or treating degenerative brain diseases comprising a hydrolysate of ginsenosides: A pharmaceutical composition for preventing or treating a degenerative brain disease comprising a compound of formula I or a or a pharmaceutically acceptable salt thereof as an active ingredient: (I) wherein, R1 is H or Glc-Glc-; R2 is H or... Agent: Anderson, Kill & Olick, P.C.

20080182801 - Core 2 glcnac-t inhibitors: p

20080182803 - Rubrofusarin glycoside-containing composition: There is provided an oral composition capable of stimulating intracellular biosynthesis of glutathione in order to maintain in-vivo (i.e., in tissues and cells) glutathione level at a high level, by adding an active ingredient other than an amino acid precursor from a viewpoint of increasing intracellular glutathione synthesis, as a... Agent: Drinker Biddle & Reath (dc)

20080182802 - Spiroheterocyclic glycosides and mehtods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.... Agent: Townsend And Townsend And Crew, LLP

20080182804 - Cyanooxime inhibitors of carbonyl reductase and methods of using said inhibitors in treatments involving anthracyclines: Compositions of matter and methods of treating cancer patients are used to prevent or limit cardiotoxicity during or after cancer treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Thus, the compositions... Agent: Pedersen & Company, PLLC

20080182805 - O-glcnacase-specific inhibitor and substrate engineered by the extension of the n-acetyl moiety: An O-GlcNAcase-specific inhibitor and substrate are engineered by the extension of the N-Acetyl Moiety of O-(2-acet-amido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc). The reagent substrate includes a fluorophor and the inhibitor. This reagent substrate is for high-throughput analysis of O-GlcNAcase within cellular assays and imaging agent for the in vivo analysis of O-GlcNAcase.... Agent: Venable LLP

20080182806 - Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents: Compositions and methods for treating various diseases and disorders, such as for a myeldoysplastic syndrome are provided. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one of an esterificated azacytidine, an acetylated azacitidine, an esterificated decitabine, and an acetylated decitabine,... Agent: Dla Piper US LLP

20080182807 - Adenoviral vectors having a protein ix deletion: Thus, for example, the adenoviral vector of this invention can contain a foreign gene for the expression of a protein effective in regulating the cell cycle, such as p53, Rb, or mitosin, or in inducing cell death, such as the conditional suicide gene thymidine kinase. (The latter must be used... Agent: Townsend And Townsend And Crew, LLP

20080182810 - Antisense modulation of acyl coa cholesterol acyltransferase-2 expression: Antisense compounds, compositions and methods are provided for modulating the expression of acyl CoA cholesterol acyltransferase-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding acyl CoA cholesterol acyltransferase-2. Methods of using these compounds for modulation of acyl CoA cholesterol acyltransferase-2 expression and for treatment of... Agent: Jones Day For Isis Pharmaceuticals, Inc.

20080182812 - Disease model animals of metabolic syndrome and a method of screening preventive and therapeutic agents for metabolic syndrome using the same: The above object is achieved by the non-human mammal model of disorders, whose TBP-2 gene is functionally deficient on chromosome, wherein the disorders are caused by impaired fatty acid utilization, and a method of screening an agent for preventing or treating Metabolic syndrome comprising; administering a test article to the... Agent: Brown & Michaels, PC 400 M & T Bank Building

20080182811 - Metabotropic glutamate receptor activator: Amino acids other than glutamic acid are used as a metabotropic glutamate receptor activator. More preferably, aspartic acid, valine and cysteine are used as a group I metabotropic glutamate receptor activator; alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080182808 - Oligoribonucleotides for the treatment of degenerative skin conditions by rna interference: The invention relates to oligoribonucleotides, which are capable of inducing breakdown of the mrna enzymes that break down connective tissue, and to pharmaceutical and cosmetic compositions, which are provided for topical application and which contain the oligoribonucleotides. The compositions are particularly suited for treating degenerative skin disorders.... Agent: Greenblum & Bernstein, P.L.C

20080182809 - Rna aptamers and methods for identifying the same: RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.... Agent: King & Spalding LLP

20080182813 - Universal target sequences for sirna gene silencing: The present invention provides a method for the production of a small interference RNA (siRNA) molecules for silencing the expression of a specific gene having AAUAAA as a polyadenylation signal site sequence. The method includes: a) identifying an oligonucleotide sequence of the specific gene, wherein the oligonucleotide sequence is about... Agent: Winston & Strawn LLP Patent Department

20080182814 - Beta-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV... Agent: Dilworth & Barrese, LLP

20080182816 - Methods for preparing a novel family of polysaccharride prodrugs for colonic delivery: This invention describes a novel family of polysaccharide prodrugs with enhanced colonic delivery advantage. The prodrugs are synthesized by chemically linking a parent compound with a specially selected polysaccharide (M.W. 105-107 Da) containing galactose residues. Its characteristics are that it is synthesized by chemically linking polysaccharides with the parent compound... Agent: Joemy C. Tam

20080182817 - Cyanocobalamin low viscosity aqueous formulations for intranasal delivery: A stable pharmaceutical mercury-free aqueous solution of cyanocobalamin comprised of cyanocobalamin and water wherein said solution of cyanocobalamin is suitable for intranasal administration, has a viscosity less than about 1000 cPs, and wherein said solution of cyanocobalamin has a bioavailability of cyanocobalamin when administered intranasally of at least about 7%... Agent: Jones Day

20080182818 - Th1 cell differentiation accelerator: The present invention provides an agent for promoting human Th1 cell differentiation and an agent for suppressing human Th2 cell differentiation, comprising lipoarabinomannans and/or lipomannans derived from BCG cell bodies. The agent of the present invention is useful as a prophylactic/therapeutic agent for cancers and the like, and also as... Agent: Leydig Voit & Mayer, Ltd

20080182819 - Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders: Low molecular weight chitosan compositions may be used in methods for treating a wide variety of mental and/or physical disorders in an animal. The low molecular weight chitosan compositions may be formulated as a capsule for oral administration in treating mental disorders, such as dementia or as a spray for... Agent: Jeffer, Mangels, Butler & Marmaro, LLP

20080182820 - Mixtures of sulfated oligosaccharides: The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080182821 - Anti-inflammatory and/or analgesic composition for the intestine comprising branched maltodextrins: The invention concerns a fiber-enriched anti-inflammatory and/or analgesic composition for the intestine, characterized in that it comprises branched maltodextrins having between 15 and 35% of glucoside bonds, 1 to 6, a reducing sugar content less than 20%, a polymolecularity index less than 5 and a number molecular weight Mn not... Agent: Young & Thompson

20080182822 - Liquid pharmaceutical compositions comprising a bisphosphonate compound: The present invention relates to liquid pharmaceutical compositions comprising a bisphosphonate compound.... Agent: Foley And Lardner LLP Suite 500

20080182781 - Process for the preparation of peptides: The present invention relates to an improved process for the preparation of N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-α-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1→6)-disulfide of formula (1), which involves assembling amino acid residues and a thioalkyl carboxylic acid with appropriate protecting groups on a solid phase resin, cleaving the peptide thus obtained from the resin with concomitant removal of side... Agent: Pharmaceutical Patent Attorneys, LLC

20080182815 - N-alkylthio beta-lactams, alkyl-coenzyme a asymmetric disulfides, and aryl-alkyl disulfides as anti-bacterial agents: The present invention provides N-alkylthio β-lactams and disulfide compounds (e.g., alkyl-coenzyme A asymmetric disulfides or aryl-alkyl disulfides), compositions containing such compounds, and method of their use as anti-bacterial agents.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080182823 - Polymer-linked-biophosphonate inhalant formulations and methods for using the same: The present invention provides for methods of administering a bisphosphonate active agent to a subject in need thereof. Aspects of the invention include administering the bisphosphonate active agent to the subject by a pulmonary route, where the bisphosphonate active agent is bonded, either directly or through an intervening linking group,... Agent: Bozicevic, Field & Francis LLP

20080182824 - Mao inhibiting n-benzyl-n-propargyl-amines useful for treating obesity: The invention provides novel N-benzyl-N-propargyl-amines that are monoamine oxidase inhibitors, but generally exhibit little or no CNS effects.... Agent: Vance Intellectual Property, PC

20080182825 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Marlin J Messick

20080182826 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20080182827 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Knobbe Martens Olson & Bear LLP

20080182828 - Low dose estrogen interrupted hormone replacement therapy: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080182829 - 8beta-hydrocarbyl-substituted estratrienes as selectively active estrogens: This invention describes the new 8β-substituted estratrienes of general formula I in which R2, R3, R6, R6′, R7, R7′, R9, R11, R11′, R12, R14, R15, R15′, R16, R16′, R17, R17′ have the meanings that are indicated in the description, and R8 means a straight-chain or branched-chain, optionally partially or completely... Agent: Millen, White, Zelano & Branigan, P.C.

20080182830 - Agent for treatment and prevention of endometriosis and uterine adenomyosis: An object of the present invention is to provide an agent for use in the effective treatment and prevention of endometriosis and uterine adenomyosis. The present invention relates to an agent for use in the treatment and prevention of endometriosis or uterine adenomyosis, comprising, as an active ingredient, a compound... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080182831 - Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions: and physiologically acceptable solvates thereof, physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080182832 - Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions: d

20080182833 - Silicone emulsion, method of preparing same, and cosmetic ingredient: A silicone emulsion comprising a polyorganosiloxane, a cholic acid derivative, and water, wherein the emulsion contains not greater than 10% (w/w) of cyclic organosiloxane tetramer; a method of preparing the emulsion; and a cosmetic composition containing the emulsion.... Agent: Dow Corning Corporation Co1232

20080182835 - Method of using a cobalt-amine based metal complex as an antiviral compound and a method for the preparation of functionalized analogs thereof: wherein each of R1, R2, R3, R4, R5 and R6 is the same or different and includes an N-based ligand donor atom selected from the group consisting of ammonia, primary amine or secondary amine, or salt thereof. The present invention is also generally directed to a method of preparing an... Agent: Naval Research Laboratory Associate Counsel (patents)

20080182834 - Multi-nuclear metal complexes partially encapsulated by cucurbit[7-12]urils: The invention provides multi-nuclear metal complexes partially encapsulated by one or more cucurbit[7 to 12]urils or analogues thereof. The invention further relates to methods for treating cancer by administering a multi-nuclear metal complex having anti-tumour activity partially encapsulated by one or more cucurbit[7 to 12]urils or analogues thereof.... Agent: Stites & Harbison PLLC

20080182836 - Cephalosporin compounds comprising a c3 thio-methyl moiety substituted with n-containing heterocyclic group, and a c7 thiourea acetamido group, their preparations and uses thereof: Disclosed herein are a cephalosporin compound comprising a C3 thio-methyl moiety substituted with an N-containing heterocyclic group, and a C7 thiourea acetamido group, the preparation and uses thereof. A method of preparing the cephalosporin compound as disclosed herein comprises reacting a starting cephalosporin comprising a C7 amino group and a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080182838 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent: Merck And Co., Inc

20080182837 - New chemical compounds: a

20080182839 - Modulators of cellular adhesion: and pharmaceutically acceptable derivatives thereof; wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof; and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular... Agent: Choate, Hall & Stewart LLP

20080182840 - Pyrimidine derivatives for the treatment of abnormal cell growth: wherein R1-R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions... Agent: Pfizer Inc

20080182841 - Vaginally administered anti-dysrhythmic agents for treating pelvic pain: The invention relates to a pharmaceutical composition for relieving pelvic pain or infertility associated with uterine dysrhythmia. The composition includes a locally-administered anti-dysrhythmic treating agent and a bioadhesive extended-release carrier. The composition may be delivered in an extended release formulation that includes a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer,... Agent: Winston & Strawn LLP Patent Department

20080182842 - L-alanine derivatives as a5beta1 antagonists: The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases... Agent: Astrazeneca R&d Boston

20080182843 - Mitotic kinesin inhibitors: The present invention relates to tricyclic pyrazoles that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also relates to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20080182844 - 7-substituted aza-indazoles, compositions containing same, production method and use thereof: e

20080182845 - Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection: Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20080182846 - Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound: t

20080182847 - 4-amino-1h-pyrimidin-2-one based compounds, compositions comprising them and methods of their use: 4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed. Particular compounds are of formula I:... Agent: Lexicon Pharmaceuticals, Inc.

20080182849 - Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton's tyrosine kinase by such compounds: A method for determining the presence of Btk in a sample, comprising contacting the sample with a compound or form thereof of Formula I under conditions that permit detection of Btk activity, detecting a level of Btk activity in the sample, and therefrom determining the presence or absence of Btk... Agent: Millen, White, Zelano & Branigan, P.C.

20080182848 - Novel process: m

20080182850 - 3-(heteroaryl)alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4: Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and... Agent: Foley & Lardner LLP

20080182851 - Acetylene derivatives as stearoyl coa desaturase inhibitors: The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof,... Agent: Darby & Darby P.C.

20080182852 - Anthranilamide inhibitors of aurora kinase: e

20080182853 - Methods of neuroprotection by cyclin-dependent kinase inhibition: The present invention relates to methods of suppressing neuronal death, such as is observed with ischemia-related diseases and disorders, including neuronal and cardiac conditions arizing from a sudden loss of oxygen and/or energy loss, and degenerative diseases, such as Alzheimer's disease to name just one. The methods involve the use... Agent: Panacea Pharmaceuticals, Inc.

20080182854 - 4-amino-5-cyanopyrimidine derivatives: The present invention provides 4-amino-5-cyanopyrimidine derivatives of the formula: wherein R1, R2 and R3 are defined herein, or pharmaceutically acceptable salts thereof, having a safe and potent adenosine A2a receptor agonistic activity; and also provides an adenosine A2a receptor agonist, an intraocular pressure reducing agent, or a medicine for treating... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080182855 - Antibacterial quinoline derivatives: the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of a bacterial disease including a mycobacterial disease, particularly those diseases caused by pathogenic mycobacteria... Agent: Philip S. Johnson Johnson & Johnson

20080182856 - Novel crystalline forms of aripiprazole: The present invention provides novel crystalline forms of aripiprazole and aripiprazole hydrochloride, processes for their preparation and pharmaceutical compositions containing them.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20080182857 - Triazole derivatives: Novel triazole derivatives of the formula (I), in which R1-R6 and Y have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20080182858 - Compositions of azimilide dihydrochloride: The present invention is directed to solvates and various polymorphic forms of (E)-1-[[[5-(4-chlorophenyl)-2-furanyl]methylene]amino]-3-[4-(4-methyl-1-piperazinyl)butyl]-2,4-imidazolidinedione dihydrochloride and pharmaceutical compositions thereof.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080182859 - Small organic molecule regulators of cell proliferation: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a compound. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal... Agent: Ropes & Gray LLP

20080182860 - Pyrimidine compounds as purine receptor antagonist: Compounds of formula (1); wherein R1 is optionally substituted C1-C3alkyl C2-C3alkenyl, or C2-C3alkynyl, or —NR6R1, —ORB, —SR9 or halogen; R3 is II; optionally substituted C,-Csalkyl, C2-C6alkenyl, C2C6alkynyl, or C3-C7 cycloalkyl, halogen; OH or OR10; R4 is H, optionally substituted C1C6alkyl, C3-C6alkenyl, C3-C6alkynyl, C3-C7 cycloalkyl, aryl or heteroaryl, R5 is H... Agent: Banner & Witcoff, Ltd.

20080182861 - Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme: m

20080182862 - N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors: N3-Heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080182863 - Fused bicyclic inhibitors of hcv: Certain appropriately substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.... Agent: Philip S. Johnson Johnson & Johnson

20080182865 - Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors: Disclosed is the use of a combination of histone deacetylase inhibitors and kinase inhibitors with anti-EGFR activity.... Agent: Sheridan Ross PC

20080182864 - Methods and compositions utilizing quinazolinones: Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080182866 - Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis: In accordance with the present invention, tetracyclic caboline derivatives that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, these compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of... Agent: Hoffmann & Baron, LLP

20080182867 - O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080182869 - Method of racemization of the r(-) isomer of the (2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h)-acetic acid methyl ester: Racemization of the R(−) isomer of the (2-chlorophenyl)-6, 7-dihydrothieno[3, 2-c]pyridine-5(4H)-acetic acid methyl ester (Formula II) (also called R clopidogrel) is performed via conversion of a portion thereof to the S(+)isomer and it takes place in an organic solvent selected from alcohols, esters, ketones or ethers, or in their mixtures, in... Agent: Pearl Cohen Zedek Latzer, LLP

20080182868 - Novel chemical compounds: This invention relates to newly identified compounds for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20080182870 - Pyrido(3,2-d)pyrimidines useful for treating viral infections: i

20080182871 - 5, 6, or 7-substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof: The present invention relates to 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives represented by general formula D, their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.... Agent: Venable LLP

20080182873 - Process for the manufacture of hmg-coa reductase inhibitors: e

20080182872 - Use of er-beta selective ligands for treating acute lung injuries: The present invention provides a method of treating acute lung injuries, such as acute lung injury induced by peritonitis during sepsis, acute lung injury induced by intravenous bacteremia during sepsis, acute lung injury caused by smoke inhalation, acute lung injury occurring in a premature infant with deficiency of surfactant, acute... Agent: Pepper Hamilton LLP/wyeth

20080182875 - N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080182874 - Novel compounds: The invention provides compounds of formula (I), or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof, in which A, n, p, q, R1, R2, R3 and R4 are as defined in the specification; a process for their preparation; pharmaceutical compositions containing them; and their use in therapy.... Agent: Fish & Richardson P.C.

20080182876 - Histamine h3-receptor ligands and their therapeutic application: The present patent application concerns new compounds of formula (I) with R1 and R2 taken together with the nitrogen atom to which they are attached, form a saturated nitrogen-containing ring, A is a saturated C1-4 alkylene and B a C3-4 alkylene or alkenylene chain; their preparation and their use as... Agent: Stites & Harbison PLLC

20080182877 - Rimonabant forms and methods of making the same: Various solid state forms of rimonabant have been found, including a particulate amorphous form as well as several hydrates and solvates.... Agent: SynthonIPInc

20080182878 - Modulation of pathogenicity: r

20080182879 - 2-oxadiazolechromone derivatives:

20080182880 - Pioglitazone composition: Pioglitazone or a salt thereof having a particle size distribution wherein D90 is about 25 μm to about 40 μm, and pharmaceutical compositions prepared therefrom.... Agent: Dr. Reddy's Laboratories, Inc.

20080182881 - Tnf-alpha production inhibitors: o

20080182882 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods of use thereof related to the treatment of cancer and other diseases.... Agent: Fish & Richardson PC

20080182883 - Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1): wherein: R1, R2, R3, and R4 are each H, alkyl, , alkanoyl, halo, OH, aryl optionally substituted with R8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, pertluoroalkoxy; R5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R5, alkanoyl, aroyl optionally substituted with R8; R6 is H, alkyl, alkylaryl, benzyl optionally substituted with... Agent: Wyeth Patent Law Group

20080182884 - Fungicide compositions: The invention relates to a method of using fungicides for protecting peanut plants, which comprises applying to the field a composition comprising dodecylguanidine as active ingredient, and such compositions useful for treating peanuts crops against early leaf spot and late leaf spot.... Agent: Norris Mclaughlin & Marcus, P.A.

20080182885 - Modified azole compounds as antifungal and antibacterial agents: e

20080182886 - Fungicidal 5-hydroxypyrazolines, processes for their preparation and comprising them:

20080182888 - Novel crystalline compounds: The present invention relates to a novel crystalline form of zofenopril calcium of formula (I), chemically known as (4S)-1-[(2S)-3-(benzoylthio)-2-methylpropionyl]-4-(phenylthio)-L-proline calcium salt. The present invention further relates to a process for the preparation of the new crystalline form of zofenopril calcium and its use in pharmaceutical preparations.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080182889 - Prodrugs of excitatory amino acids: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.... Agent: Eli Lilly & Company

20080182887 - Stable oral pharmaceutical composition: The invention relates to a stable oral pharmaceutical composition comprising atorvastatin or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier comprising tromethamine and an antioxidant.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080182891 - Chromane and chromene derivatives and uses thereof: wherein each of R1, R2, R3, R4, y, m, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety... Agent: Choate, Hall & Stewart LLP/wyeth

20080182890 - Methods of using low-dose doxepin for the improvement of sleep: Methods of treating sleep disorders by administration of low doses of doxepin in individuals seeking sustained efficacy or in need of avoiding weight gain, rebound insomnia, or sedative tolerance resulting from doxepin treatment.... Agent: Knobbe Martens Olson & Bear LLP

20080182892 - Treatment of interstitial cystitis using (6ar, 10ar)-delta-8-tetrahydrocannabinol-11-oic acids: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-Δ8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-Δ8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-Δ8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention... Agent: Choate, Hall & Stewart LLP

20080182893 - Anti-atherogenic composition: Disclosed is an anti-atherogenic composition or an atherosclerosis progression inhibitory composition which can be used effectively for preventing or ameliorating atherosclerosis. The anti-atherogenic composition or atherosclerosis progression inhibitory composition comprises an enzyme-treated isoquercitrin as the active ingredient.... Agent: Fitch, Even, Tabin & Flannery

20080182894 - Method of providing preparation for topical application and supplement meeting client's needs: The present invention provides a method of efficiently providing, to a client, a preparation for topical application and a supplement suitable for the client. This method entails inputting the part desired by the client to be improved and an improvement effect desired for the part into a system, which will... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080182895 - Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto: The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a... Agent: Fitzpatrick Cella Harper & Scinto

20080182896 - Use of metal chelates in human or animal feeding: The present invention relates to the use in human and animal nutrition (monogastric and polygastric animals) of known chelates of bivalent metal Mg, Ca, Mn, Co, Cu, Zn and Fe with methionine hydroxy analogue. The present invention further relates to a method for preparing new chelates with methionine hydroxy analogue,... Agent: Pearne & Gordon LLP

20080182897 - Crystalline potassium salt of lipoxin a4 analogs: e

20080182898 - Treatment of metabolic syndrome with norfluoxetine: The invention relates to methods of treating metabolic syndrome, or the specific disorders associated with metabolic syndrome, comprising the administration of norfluoxetine enriched for the (R) or (S) enantiomer conjointly with niacin, fenofibrate, a H1 antagonist or inverse agonist, or a H3 agonist or partial agonist.... Agent: Ropes & Gray LLP

20080182899 - Association of beta3 receptor agonist and monoamine reuptake inhibitors, pharmaceutical composition and therapeutic use thereof: The invention concerns the association of at least one β3 adrenergic receptor agonist (or β3 agonist) with a monoamine reuptake inhibitor. The invention also concerns a pharmaceutical composition comprising the inventive association and its therapeutic use.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080182900 - Method of treatment of virus infections using shikonin compounds: Medicaments containing shikonin compounds and salts thereof including shikonin and alkannin are used for treatment of virus infections, mycoplasma infections and malignant tumor.... Agent: Yi Li

20080182901 - Crystalline acid of lipoxin a4 analogs and method of making: d

20080182902 - Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae: The present invention relates to the use of sphingolipids for the preparation of a food item, a food supplement and/or a medicament for the prevention and/or treatment of hepatotoxic effects such as hepatic steatosis, fibrosis and/or cirrhosis. In particular, the invention relates to the use of a sphingolipid with the... Agent: Weingarten, Schurgin, Gagnebin & Lebovici LLP

20080182903 - Formulation of a composition for treating various conditions by using lotion/cream including l-arginine: Disclosed is a composition and method, for various conditions, including body weight control, sexual dysfunction, stomach blotting, heartburn, body pain, and controlling cholesterol, arginine is used as active material. The composition is in the form of lotion/cream applicable to any part of the body and still functional. It does not... Agent: Wilson Daniel Swayze, Jr.

20080182904 - Baclofen for relapse protection in addiction: The present invention is directed a method to prevent relapse in a patient being treated for substance or behavioral addiction using baclofen. Baclofen can also be used to treat depression or other psychological conditions.... Agent: WilsonIPLaw

20080182905 - Medicament for preventive and therapeutic treatment of physical dysfunction caused by nerve damage: e

20080182906 - Novel specific caspase-10 inhibitors: The invention relates to compounds of the general formula (I) wherein R1, R2, R3, R4, R5, R6, i and j have the meanings given in claim 1, and to the use thereof as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy.... Agent: Millen, White, Zelano & Branigan, P.C.

20080182907 - External pharmaceutical composition containing tramadol: An analgesic composition for external application for increasing the percutaneous permeability of tramadol or a pharmaceutically acceptable salt thereof and for achieving a quick pharmacological effect. The analgesic composition includes tramadol or a pharmaceutically acceptable salt thereof, a menthol substance and a pyrrolidone compound.... Agent: Oliff & Berridge, PLC

20080182908 - Pharmaceutical compositions comprising memantine: Pharmaceutical compositions comprising memantine or a salt thereof, from which less than about 80% of the contained memantine dissolves into a pH 1.2 aqueous medium within about 60 minutes.... Agent: Dr. Reddy's Laboratories, Inc.

20080182909 - Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers: Methods for reducing or inhibiting the irreversible inactivation of water-soluble biologically active agents in biodegradable polymeric delivery systems which are designed to release such agents over a prolonged period of time, such as PLGA delivery systems are provided. The method comprises preparing PLGA delivery systems whose microclimate, i.e. the pores... Agent: Calfee Halter & Griswold, LLP

  
07/24/2008 > patent applications in patent subcategories. cataloged by category listing

20080176785 - Controlled release compositions: Controlled release compositions for controlling release of a GnRH molecule or a GnRH analog are provided. The compositions include a GnRH molecule or GnRH analog as an active agent, and a controlled release component for controlling release of the GnRH molecule or GnRH analog from the composition. The compositions provide... Agent: Thomas P. Mccracken

20080176786 - Transgenically produced antithrombin iii: This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII... Agent: Gtc Biotherapeutics, Inc. C/o Wolf, Greenfield & Sacks, P.c.

20080176787 - Parathyroid hormone analogues and methods of use: The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c Attn: Patent Intake Customer No. 30623

20080176788 - Apo-2 ligand: A novel cytokine, designated Apo-2 ligand, which induces mammalian cell apoptosis is provided. The Apo-2 ligand is believed to be a member of the TNF cytokine family. Compositions including Apo-2 ligand chimeras, nucleic acid encoding Apo-2 ligand, and antibodies to Apo-2 ligand are also provided. Methods of using Apo-2 ligand... Agent: Genentech, Inc.

20080176801 - Axmi-004, a delta-endotoxin gene and methods for its use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Alston & Bird LLP

20080176803 - Components of the presenilin-complex: m

20080176798 - Compounds and methods for diagnosis and immunotherapy of tuberculosis: Compounds and methods for diagnosing tuberculosis or for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more Mycobacterium proteins and DNA molecules encoding such polypeptides. Diagnostic kits containing such polypeptides or DNA sequences and a suitable... Agent: Townsend And Townsend And Crew, LLP

20080176797 - Compounds and methods for treatment and diagnosis of chlamydial infection: Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a Chlamydia antigen and DNA sequences encoding such polypeptides. Pharmaceutical compositions and vaccines comprising such polypeptides or DNA sequences are also provided, together with... Agent: Seed Intellectual Property Law Group Pllc

20080176794 - Long lasting fusion peptide inhibitors of viral infection: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile... Agent: Lowrie, Lando & Anastasi, LLP

20080176795 - Method for treatment of anxiety: Human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues having a modified A chain and/or a modified B chain are described. Also described are nucleic acid sequences encoded human H3 preprorelaxin, human H3 prorelaxin, human H3 relaxin, human relaxin analogues. Also described are methods for the treatment... Agent: Sughrue Mion, Pllc

20080176804 - Methods for affecting body composition: Methods for affecting body composition include the use of amylin or amylin agonist(s). Total body weight may be reduced, maintained or even increased; however, the body fat is reduced or body fat gain is prevented, while lean body mass is maintained or increased.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080176800 - Methods for the delivery of bioactive substances with biodegradable polyphosphates: The present invention is directed to a biodegradable system for the controlled release of bioactive substances. This system comprises novel biodegradable and biocompatible polyphosphoesters that carry positive charges. Process for making these polyphosphoesters, compositions containing these polyphosphoesters and biologically active substances, articles and methods for delivery of drugs and genes... Agent: Greenberg Traurig LLP (la)

20080176802 - Methods of use for conjugated exendin peptides: Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonists, compositions and methods are useful in treating diabetes and conditions... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080176791 - Novel albumin-free factor viii formulations: A Factor VIII composition formulated without albumin, comprising the following formulation excipients in addition to Factor VIII: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose,... Agent: Baxter Healthcare Corporation

20080176799 - Pharmaceutical compositions: The invention provides pharmaceutical compositions comprising TGF-β superfamily members and sugars, the compositions allowing improved recovery and/or increased biological activity of the TGF-β superfamily member incorporated therein. The invention also relates to uses of sugars to improve the recovery or increase the biological activity of TGF-β superfamily members in a... Agent: Darby & Darby P.c.

20080176789 - Purification of factor xlll polypeptides from biological materials: The invention relates to a method for purifying a factor XIII polypeptide from a biological material, the method comprising subjecting the material to sequential chromatography on an anion-exchange matrix and a hydrophobic interaction matrix.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080176790 - Remodeling and glycopegylation of fibroblast growth factor (fgf): The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080176796 - Selective modulation of tumour necrosis factor receptors in therapy: This invention relates to the identification and characterisation of specific cellular responses which are associated with tumour necrosis factor receptor 1 (TNFR1) and tumour necrosis factor receptor 1 (TNFR2). Selective modulation of these tumour necrosis factor receptors (TNFRs) Selective modulations of these responses may be useful in the promotion or... Agent: Klarquist Sparkman, LLP

20080176793 - Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects: This invention provides novel methods of treatment to ameliorate or prevent cognitive disorder/dysfunction in pre- or asymptomatic subject having one or more mutations in the Huntington gene. The methods involve increasing the expression or activity of the neurotrophin BDNS in the brain of said subject.... Agent: Beyer Weaver LLP

20080176792 - Vegfr-1 targeting peptides: The present invention concerns novel methods of identifying peptide sequences that selectively bind to targets. In alternative embodiments, targets may comprise cells or clumps of cells, particles attached to chemicals compounds, molecules or aggregates, or parasites. In preferred embodiments, target cells are sorted before exposure to the phage library. The... Agent: Fulbright & Jaworski L.l.p.

20080176805 - Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone... Agent: Goodwin Procter LLP

20080176806 - Therapeutic uses of tri-, tetra-, penta-, and polypeptides: Novel uses of certain peptides to treat patients suffering from neurological or psychiatric disorders are disclosed. The peptides include the tripeptide hormone MIF and compounds made by modifications of MIF, such as modification of amino terminus residues, carboxyl terminus residues and internal residues, including addition and substitution of amino acid... Agent: Diamond Law Office Llc

20080176807 - Facially amphiphilic polymers and oligomers and uses thereof: The present invention discloses methods of use of facially amphiphilic polymers and oligomers, including pharmaceutical uses of the polymers and oligomers as antimicrobial agents and antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polymers and oligomers and their compositions, including pharmaceutical compositions.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080176808 - Soil amendment compositions and methods for using the same: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests... Agent: Bozicevic, Field & Francis LLP

20080176809 - Use of d-ribose to treat cardiac arrhythmias: D-ribose, given in doses of five to 15 grams daily, reduces or prevents the occurrence of atrial fibrillation in persons experiencing atrial fibrillation.... Agent: Kathleen R. Terry

20080176811 - Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition: wherein the flavone or isoflavone residue is substituted one or more times and/or reduced one or more times; Z represents a mono-, di- or polysaccharide, which is acetally-bound at the benzopyran group to X and ester-substituted by —O—C(═O)-A2; [A1-C(═O)] is an acyl group on the flavone or isoflavone; A1 and... Agent: Cognis Corporation Patent Department

20080176810 - Use of 3, 4', 5-trihydroxy-stilbene-3-beta-d-glucoside in prepartion of medicines for treating and/or preventing ischemic heart disease: The present invention provides new use of 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside. 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside has efficacies of anti-myocardial ischemia by intravenous injection and/or oral administration. It is advantageous that 3,4′,5-trihydroxy-stilbene-3-β-D-glucoside as anti-myocardial ischemia drug is used to prepare the medicine for treating and/or preventing ischemic heart disease.... Agent: Barnes & Thornburg LLP

20080176812 - Allele-specific silencing of disease genes: The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules.... Agent: Viksnins Harris & Padys Pllp

20080176813 - Carbocyclic nucleosides and process for obtaining such: The present invention provides a six membered, at least partially unsaturated, carbocyclic nucleoside compound, including the (−) enantiomer, the (+) enantiomer, and pharmaceutically acceptable salts and esters thereof. The compounds are represented by formula (I), wherein Z represents one double bond in the six membered carbocylic ring, B is a... Agent: The Webb Law Firm, P.c.

20080176814 - Dna-based aptamers for human cathepsin g: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or... Agent: Intellectual Property Group Fredrikson & Byron, P.a.

20080176815 - Compounds that interact with kinases: A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereof.... Agent: Nixon & Vanderhye, Pc

20080176816 - Method of making and using an adenosine analogue: This document describes compounds, extracts, and pharmaceutical compositions relating to Gastrodia spp., and methods for the treatment subjects having metabolic disorders or medical conditions such as Huntington's disease, a trinucleotide repeat disease or abnormal blood glucose levels.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080176817 - Compounds useful in the treatment of hiv: There is provided inter alia use of 2′,3′-dideoxy-3′-hydroxymethylcytosine or a prodrug or salt thereof in the manufacture of a medicament for the treatment of HIV infection wherein the reverse transcriptase of the HIV bears at least one mutation that allows an obligate chain terminating nucleoside- or nucleotide phosphate to be... Agent: Birch Stewart Kolasch & Birch

20080176818 - Sulfoglycolipid antigens, their extraction from mycobacterium tuberculosis, and their use against tuberculosis: The present invention relates to compounds of the following general formula: (I) wherein R1 and R2 are fatty acyl groups, a process to extract them from Mycobacterium tuberculosis, and their use in the treatment or the prophylaxis of tuberculosis.... Agent: Young & Thompson

20080176819 - Method of preventing or treating metabolic syndrome: Water-insoluble cellulose derivatives such as ethyl cellulose can be used to treat or prevent metabolic syndrome and/or one of the abnormalities of metabolic syndrome.... Agent: The Dow Chemical Company

20080176820 - Use of l-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro: The disclosure relates to a method for in vivo differentiation of monocytes in mature dendritic cells, wherein a) monocytes are provided in an appropriate culture medium, b) the monocycles are differentiated in dendritic cells in the presence of a differentiation factor, c) L-α-lysophosphatidylcholine is added to the medium and mature... Agent: Oliff & Berridge, Plc

20080176821 - Ligands for metabotropic glutamate receptors and inhibitors of naaladase: The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or... Agent: Foley & Lardner LLP

20080176822 - Novel composition for treating metabolic syndrome: The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated Protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080176823 - Breast and prostate cancer treatment method: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.... Agent: Hollis-eden Pharmaceuticals, Inc.

20080176824 - Pharmaceutical compositions 3: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of... Agent: Hollis-eden Pharmaceuticals, Inc.

20080176825 - Oral neurotherapeutic cefazolin compositons: The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.... Agent: Barnes & Thornburg LLP

20080176828 - Treating melanoma with bis(thiohydrazide amides): Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080176827 - New pyridine analogues vii 543: s

20080176826 - Pyridine compounds for combating arthropod pests and nematodes:

20080176830 - Compounds, compositions, and methods: Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080176829 - Compounds: m

20080176831 - 2-substituted pyrimidines and their use as pesticides:

20080176832 - Pyrazolo [3,4-d]azepine derivatives as histamine h3 antagonists: The present invention relates to novel pyrazole derivatives of formula I having pharmacological activity as H3 antagonists processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080176833 - Dihydropyridine derivatives as useful as protein kinase inhibitors: e

20080176834 - Quinolone carboxylic acids, derivatives thereof, and methods of making and using same: A process of preparing a quinolone carboxylic acid or its derivatives having Formula I, Ia, or IV, as shown herein, comprises using a starting quinolone that already has one or more desired substituents at one or more particular positions on the quinolone ring and preserving the orientation of such substituents... Agent: Bausch & Lomb Incorporated

20080176835 - Prenyl transferase inhibitors: p

20080176836 - Use of selected cgrp antagonists for combating menopausal hot flushes: The invention relates to the use of selected CGRP antagonists, the physiologically acceptable salts thereof or the hydrates of the hydrates of the salts thereof for combating menopausal hot flushes.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080176837 - Treatment of pain: The invention relates to a new medicamentation for the treatment of pain, in particular fibromyalgia. The medicamentation comprises the administration of pramipexole and meloxicam. The medicamentation is a combination of pramipexole and meloxicam which may be used in a fixed dose combination as well as in a free dose combination.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20080176838 - Dpp-iv inhibitors: wherein R1-9, Z, n, X, A, and Rb have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of... Agent: Kilyk & Bowersox, P.l.l.c.

20080176839 - Spiropiperidine derivatives as nk3 antagonists: e

20080176840 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080176842 - Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors: e

20080176841 - Epoxide inhibitors of cysteine proteases: Provided herein are novel epoxide inhibitors of cysteine proteases, compositions comprising the epoxide inhibitors, and packaged pharmaceuticals. Also provided are methods of inhibiting a papain-family cysteine protease and methods of treating or preventing a disease by administering a composition containing an epoxide inhibitor of the invention. The compositions may be... Agent: Ropes & Gray LLP

20080176843 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonathan P. O'brien Miller, Canfield, Paddock And Stone, P.L.C

20080176844 - Pharmacokinetically improved compounds: in which each R5, R6, R7 and R8 are independently selected from H and lower alkyl, wherein the lower alkyl may be optionally substituted with one or more halogen, lower alkoxy, hydroxy, CN, NO2, amino, acylamino, amido, carbonyl, and alkylthio; and additionally or alternatively R6 and R5 together form a... Agent: Kenyon & Kenyon LLP

20080176845 - Antagonists of a2b adenosine receptors for treatment of inflammatory bowel disease: The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).... Agent: Schwegman, Lundberg & Woessner, P.a.

20080176847 - Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors: Bridged bicyclic aryl or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Seed Intellectual Property Law Group Pllc

20080176846 - Compositions and methods for modulating c-kit and pdgfr receptors: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat,... Agent: Genomics Institute Of The Novartis Research Foundation

20080176849 - Deacetylase inhibitors: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.... Agent: Novartis Corporate Intellectual Property

20080176848 - N-sulphonylpyrroles and their use as histone deacetylase inhibitors: e

20080176850 - S-triazolyl alpha-mercaptoacetanilides as inhibitors of hiv reverse transcriptase: A series of S-triazolyl α-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.... Agent: Wilson Sonsini Goodrich & Rosati

20080176851 - Method for inhibiting lymphangiogenesis and inflammation: A method for inhibiting lymphangiogenesis and/or inflammation by blocking sGCα1β1 signaling is provided. In a preferable embodiment, the blockage of sGCα1β1 signaling is accomplished by means of applying sGC inhibitor such as NS-2028 on skin.... Agent: Amin, Turocy & Calvin, LLP

20080176852 - Biguanide and dihydrotriazine derivatives: Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of... Agent: Woodcock Washburn LLP

20080176853 - Triazine derivatives and their therapeutical applications: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.... Agent: Leydig Voit & Mayer, Ltd

20080176854 - Nitro-substituted phenyl-piperazine compounds, their preparation and use in medicaments: The present invention relates to nitro-substituted phenyl-piperazine compounds of general formula I, a process for their preparation, medicaments comprising said nitro-substituted phenyl-piperazine compounds as well as the use of said nitro-substituted phenylpiperazine compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080176855 - Derivatives of 5-pyridazinyl-1-azabicyclo[3.2.1]octane, preparation method thereof and use of same in therapeutics: e

20080176856 - Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors:

20080176857 - 4-piperazinnylthieno[2,3-d]pyrimidine compounds as platelet aggregation inhibitors:

20080176858 - Selective antagonists of a2a adenosine receptors:

20080176859 - Heterocyclyamide-substituted imidazoles: The invention relates to heterocyclylamide-substituted imidazoles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular for the use as antiviral agents, especially against cytomegaloviruses.... Agent: Morrison & Foerster LLP

20080176860 - Pyridin-2-one compounds: The present invention relates to compounds of the formula (I) that are useful antimicrobial agents and effective against a variety of multi-drug resistant bacteria:... Agent: Dann, Dorfman, Herrell & Skillman

20080176861 - Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis: Disclosed herein are new methods of treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver in a subject by modulating PPARδ with sulfonyl-substituted bicyclic compounds and compositions as pharmaceuticals.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20080176863 - Capped pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080176862 - New compounds 617: e

20080176867 - N-[(4,5-diphenylpyrimidin-2-yl)methyl]amine derivatives, the preparation thereof and their therapeutic use:

20080176866 - Novel hetaryl-phenylenediamine-pyrimidines as protein kinase inhibitors: The invention relates to novel hetaryl-phenylenediamine-pyrimidines and to their structurally related oxygen and sulphur analogues of the general formula I, processes for their preparation, and their use as medicaments.... Agent: Millen, White, Zelano & Branigan, P.c.

20080176865 - Substituted arylpyrazoles: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20080176864 - Substituted n-arylpyrrolidines as selective androgen receptor modulators: The present invention provides a compound of the Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and... Agent: Eli Lilly & Company

20080176868 - Preparation and use of compounds as protease inhibitors: e

20080176870 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.... Agent: Amgen Inc.

20080176869 - Tetrahydro-4h-pyrido[1,2-a] pyrimidines useful as hiv integrase inhibitors: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein n is an integer equal to zero, 1, 2 or 3, and R1, R3, R4, R12, R14, R16, R30, R32, R34 and R36 are defined herein. These compounds are useful in the prevention and treatment of infection... Agent: Merck And Co., Inc

20080176871 - 4-cyanophenylamino-substituted bicyclic heterocyclic compounds as hiv inhibitors: where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O,... Agent: Wilson Sonsini Goodrich & Rosati

20080176872 - Chemical compounds: This invention relates to novel compounds having the formula (I); and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.... Agent: Astrazeneca R&d Boston

20080176873 - Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular... Agent: Fulbright & Jaworski L.l.p.

20080176874 - Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same: The invention relates to derivatives of pyrido[2,3-d]pyrimidine, to the preparation thereof, and to the therapeutic application of the same.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080176876 - Substituted 2-alkyl quinazolinone derivatives as parp inhibitors: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein R1, R3, L, X, Y and Z have defined meanings.... Agent: Philip S. Johnson Johnson & Johnson

20080176875 - Substituted quinazolines: This invention relates to the discovery of prodrugs of 3- or 5-substituted analogues of the selective platelet lowering agent anagrelide which have reduced potential for cardiovascular side-effects and which should therefore lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates... Agent: Darby & Darby P.c.

20080176877 - Substituted quinazolines: This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have... Agent: Darby & Darby P.c.

20080176881 - Compounds and compositions as protein kinase inhibitors: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion... Agent: Genomics Institute Of The Novartis Research Foundation

20080176878 - Crystalline rosuvastatin calcium: Provided is a crystalline form of rosuvastatin calcium characterized by X-ray powder diffraction peaks at about 4.7, 19.4 and 22.3° 2 theta±0.2° 2 theta and processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20080176880 - Hiv replication inhibiting pyrimidines: the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein -a1=a2-a3=a4- forms a phenyl, pyridinyl; pyrimidinyl, pyridazinyl or pyrazinyl with the attached vinyl group; n is 0 to 4; and where possible 5. R1 is hydrogen, al, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, substituted C1-6alkyl, or... Agent: Philip S. Johnson Johnson & Johnson

20080176879 - Pyrimidylaminobenzamide derivatives for sytemic mastocytosis: The present invention relates to the use of pyrimidylaminobenzamide derivatives for the preparation of a drug for the treatment of systemic mastocytosis.... Agent: Novartis Corporate Intellectual Property

20080176883 - Aminopyrrolidines as chemokine receptor antagonists: pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative... Agent: Abbott Bioresearch

20080176882 - Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one: The present invention is directed to salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by NOP, for example depression, anxiety, alcohol abuse, etc. The present invention is further directed to process(es) for the preparation of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one and its corresponding salts.... Agent: Philip S. Johnson Johnson & Johnson

20080176884 - 7,8-saturated-4,5-epoxy-morphinanium analogs: Novel 7,8-saturated-4,5-epoxy-morphinanium analogs are disclosed. Pharmaceutical compositions containing the 7,8-saturated-4,5-epoxy-morphinanium analogs and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as modulators of opioid receptors.... Agent: Kelley Drye & Warren LLP

20080176885 - Novel synergistic opioid-cannabinoid codrug for pain management: Compounds including an opioid, and a cannabinoid covalently bound by a linker; pharmaceutical formulations including codrugs; methods of manufacture as well as methods of treatment are disclosed.... Agent: Davidson, Davidson & Kappel, Llc

20080176886 - Phenanthroindolizidine alkaloids: A group of novel phenanthroindolizidine alkaloid compounds as shown and their use in treating cancer. Also disclosed are methods of using phenanthroindolizidine alkoid compounds in suppressing NO and TNF-α production, inhibiting MEKK1 activity and cyclooxygenase II expression, and treating NO-related disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080176887 - Method for decreasing nicotine and other substance use in humans: A method for decreasing nicotine and other substance use in humans is disclosed. Tetrahydroberberine (THB) and its analogs, l-Tetrahydropalmatine (l-THP) and l-Stepholidine (l-SPD), are present in and can be isolated from several plants in the Magnoliidae superorder. According to the disclosed method, THB and its analogs are used to block... Agent: Quarles & Brady LLP

20080176888 - Sirolimus formulation: The present invention relates to a stable pharmaceutical composition comprising sirolimus. The pharmaceutical composition comprises sirolimus in the amorphous form, a fatty acid ester and a pharmaceutically acceptable polymer wherein the fatty acid ester is present at a concentration of less than 10% w/w compared to the total weight of... Agent: Sandoz Inc

20080176889 - 9-anilinoacridine alkylating agents: This invention relates to 9-anilinoacridine alkylating agents, their synthesis and their use in pharmaceutical compositions for treating diseases.... Agent: Fish & Richardson Pc

20080176890 - Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands... Agent: Millen, White, Zelano & Branigan, P.c.

20080176892 - Novel azaheterocyclic compounds as kinase inhibitors: The invention relates to compounds of the formula (I), to the preparation and use thereof for the preparation of a medicament for the treatment of diseases, in particular tumours and/or diseases in the development or course of which kinases are involved.... Agent: Millen, White, Zelano & Branigan, P.c.

20080176891 - Novel compounds: e

20080176893 - Formulation of a thienopyridine platelet aggregation inhibitor: A formulation of a compound of formula (I) process of manufacture and methods of using it are disclosed.... Agent: Eli Lilly & Company

20080176894 - Novel aminopyridine-derivatives: f

20080176895 - Quinolinone-carboxamide compounds as 5-ht4, receptor agonists: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080176896 - Modulators of cellular adhesion: and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular... Agent: Choate, Hall & Stewart LLP

20080176897 - Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof: Substituted quinolone carboxylic acids and their derivatives are described. These compounds modulate the effect of γ-aminobutyric acid (GABA) via a novel site on the GABAA receptor complex in a therapeutically relevant fashion and may be used to ameliorate CNS disorders amenable to modulation of the GABAA receptor complex.... Agent: Heller Ehrman LLP

20080176898 - Phenyl acetamides: The present invention relates to phenylacetamides, to a process for their preparation and to their use for producing medicaments for the treatment and/or prophylaxis of diseases in humans and animals, especially of cardiovascular disorders.... Agent: Bayer Health Care Llc

20080176900 - 5h-thioeno(3,4-c)pyrrole-4,6-dione derivatives and their use as tumor necrosis factor inhibitors: in which R1 represents H, C1-6alkyl, OR4, OC(O)R5, NO2, NHC(O)R6, or NR7R8; R2 represents H, a halogen, or C1-6alkyl; R3 represents H, methyl, isopropyl, allyl, benzyl, CH2CO2(C1-6alkyl), or CH2(CH2)nR9; R4, R5, R6, R7, and R8 each independently and at each occurrence represents H, or C1-6alkyl; R9 represents H, C1-6alkyl, OH,... Agent: Matthias Scholl

20080176899 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Nandakumar Govindaswamy Vertex Pharmaceuticals Inc.

20080176901 - Compounds and compositions as channel activating protease inhibitors: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2),... Agent: Genomics Institute Of The Novartis Research Foundation

20080176902 - Salt iii: The invention provides N-{2-[((2S)-3-{[1-(4-chlorobenzyl)piperidin-4-yl]amino}-2-hydroxy-2-methyl-propyl)oxy]-4-hydroxyphenyl}acetamide hemi-fumarate or a solvate thereof, pharmaceutical compositions containing the salt or solvate and use of the salt or solvate in therapy.... Agent: Fish & Richardson P.c.

20080176903 - Novel compounds with analgesic effect: e

20080176904 - Benzazole potentiators of metabotropic glutatmate receptors: The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also... Agent: Merck And Co., Inc

20080176905 - Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof: The present invention presents crystal forms of Rosiglitazone hydrobromide, denominated Form I and Form II, methods of their preparation, as well as pharmaceutical compositions comprising these crystalline forms.... Agent: Kenyon & Kenyon LLP

20080176907 - Nos inhibitors for treatment of motor deficit disorders: The present invention relates to preventive therapies and treatments of motor deficit disorders. In particular, the present invention relates to compositions and methods for preventative therapy and treatment of motor deficit disorders, such as cerebral palsy, in fetuses and newborn infants using inhibitors to neuronal nitric oxide synthase (nNOS).... Agent: Casimir Jones, S.c.

20080176906 - Substituted pyrrole derivative: (wherein X represents a halogen atom, Y represents a carbon atom or a nitrogen atom, Alk represents an optionally substituted C1-4 alkylene group, and RB represents a hydrogen atom or an acyl group), and R5 represents a phenyl group which has a cyano group at a 4-position or a 3-position... Agent: Edwards Angell Palmer & Dodge LLP

20080176908 - Method of using squalene monooxygenase inhibitors to treat acne: A method for the treatment of acne comprising the administration, to a patient afflicted therewith, of a effective amount of a squalene monooxygenase inhibitor such as tolnaftate, naftifine, terbinafine, butenafine or ciclopirox. An advantage of the present invention relates to the surprisingly speedy onset of effectiveness in relieving acne symptoms.... Agent: Christopher J. Mcdonald Hoffman, Wasson & Gitler, P.c.

20080176910 - Methods for prevention and treatment of arteriosclerosis and restenosis: Methods for the prevention and/or treatment of arteriosclerosis and restenosis following percutaneous coronary intervention or sudden death and for the inhibition of vascular smooth muscle cells, neointima formulation of blood vessels or vascular remodeling comprising administering to a mammal, such as a human, in need thereof pharmaceutically effective amounts of... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20080176909 - Methods for prevention and treatment of arteriosclerosis, hypertension and restenosis: t

20080176911 - Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors: inhibit the formation of the β-amyloid peptide (β-A4) and are, therefore, useful in the treatment of pathologies in which a β-amyloid peptide (β-A4) formation inhibitor provides a therapeutic benefit. Particular such pathologies are senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy, cerebrovascular disorders, frontotemporal dementias and Pick's disease,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080176912 - Gpr40 agonists: The invention is directed to compounds of Formula (I) useful as GPR40 agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, insulin resistance, hyperglycemia, obesity, diabetes such as NIDDM, and other disorders related to lipid metabolism, energy homeostasis, and complications thereof, using compounds... Agent: Philip S. Johnson Johnson & Johnson

20080176913 - Transdermal compositions of pramipexole having enhanced permeation properties: A pharmaceutical composition for transdermal or transmucosal delivery of an active agent to treat a movement disorder such as Parkinson's disease. The composition provides enhanced transdermal or transmucosal delivery of the active agent by including an alkanolamine as a permeation enhancer with a carrier of water and at least one... Agent: Winston & Strawn LLP Patent Department

20080176914 - Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol: The present invention is directed to an anhydrate crystal form (designated as Form B herein) of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen.... Agent: Pepper Hamilton LLP/wyeth

20080176915 - Substituted benzo[d]isoxazol-3-yl amine compounds as analgesics: e

20080176916 - A-amino-n-hydroxy-acetamide derivatives:

20080176917 - 3-triazolylthiaalkyl-3-azabicyclo (3-1-o) hexanes and their use as dopamine d3 receptor ligands: and wherein, if n is 0, R3 comprises at least one SF5 group as a substituent; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080176918 - Nonsedating alpha-2 agonists: The present invention provides an α-2A/α-1A selective agonist that includes a compound represented by Structure 1 or a pharmaceutically acceptable salt, ester, amide, stereoisomer or racemic mixture thereof. The present invention further provides a pharmaceutical composition that contains a pharmaceutical carrier and a therapeutically effective amount of an α-2A/α-1A selective... Agent: Allergan, Inc.

20080176919 - Imidazole derivatives as enzyme reverse transcriptase modulators: This invention relates to benzonitrile derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereof, wherein R1 to R3 are defined in the description, to their use in medicine, and to compositions containing them. The compounds of the present invention bind to the enzyme reverse transcriptase and are... Agent: Pfizer Inc Steve T. Zelson

20080176920 - Neuronal pain pathway modulators: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are... Agent: Baker Botts L.l.p.

20080176921 - Auxin acid-catalyzed stable microemulsion pesticide formulation: An auxin acid-catalyzed stable microemulsion pesticide formulation is provided that is clear and stable under a wide range of temperature conditions encountered during distribution, storage, and use of the pesticide formulation. A precursor for the microemulsion includes an auxin ester, a protox inhibitor, and an auxin acid stabilizing agent as... Agent: Hovey Williams LLP

20080176922 - Uses of 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssris:

20080176923 - Proline derivatives used as pharmaceutical active ingredients for the treatment of tumors: The invention relates to proline derivatives and their salts, to pharmaceutical agents containing said derivatives and to the use of said agents for treating tumours. The invention also relates to methods for producing said compounds and pharmaceutical agents.... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20080176924 - Derivatives of 4,5-diarylpyrrole, preparation method thereof and use of same in therapeutics: e

20080176925 - Toluene sulfonic acid salt of a therapeutic compound and pharmaceutical compositions thereof: to solvates (e.g., hydrates) thereof, to polymorphs thereof, to pharmaceutical compositions thereof and to a method of treating depression, mood disorders, schizophrenia, anxiety disorders, cognitive disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses,... Agent: Pfizer Inc Steve T. Zelson

20080176926 - Hydrogenated benzo (c) thiophene derivatives as immunomodulators: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunosuppressive agents.... Agent: Dickstein Shapiro LLP

20080176927 - Compositions of stable tiacumicins: The present invention is related to pharmaceutical compositions of one or more tiacumicins that exhibit improved stability, and methods of treatment using such formulations. The formulations contain one or more tiacumicins, such as difimicin, and one or more antioxidants, such as butylated hydroxytoluene, and, optionally, one or more pharmaceutically acceptable... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20080176928 - Avermectin/hydrocortisone compositions for treating afflictions of the skin, e.g., rosacea: Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and hydrocortisone or salt, ester or derivative thereof, are useful for treating afflictions of the skin, especially rosacea.... Agent: Buchanan, Ingersoll & Rooney Pc

20080176929 - Method of treating organism by biologically active compounds specifically delivered into mitochondria, pharmaceutical composition required for the use of the method and a compound applicable for this purpose: This invention relates to biology and medicine and, in particular, can be used in medicine to make a pharmaceutical composition for targeted delivery of biologically active substances into mitochondria, driven by proton electro-chemical potential in the mitochondria. This invention also relates to the method to affect an organism by the... Agent: Ladas & Parry

20080176930 - Substantially pure fluorescein: The present invention is directed to an improved process for producing substantially pure fluorescein, as well as to substantially pure fluorescein compositions prepared by the process. The invention is particularly directed to the provision of pharmaceutical compositions for use in angiography. The substantially pure fluorescein produced by the process of... Agent: Alcon

20080176931 - (-)-epigallocatechin gallate derivatives for inhibiting proteasome: (−)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (−)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formulae below, wherein R11, R12, R13, R21, R22, R2, R3, and R4 are each independently selected from the group consisting... Agent: Buchanan, Ingersoll & Rooney Pc

20080176933 - Binding interaction of proanthocyanidins with bacteria and bacterial components: A composition having proanthocyanidin compounds having an average degree of polymerization of at least about 6. A method of administering to an immunosuppressed patient or a patient diagnosed with sepsis or septic shock a composition having a proanthocyanidin. A method of administering to a patient diagnosed with a gram negative... Agent: Naval Research Laboratory Associate Counsel (patents)

20080176935 - Combination of unsaponifiable lipids combined with polyphenols and/or catechins for the protection, treatment and repair of cartilage in joints of humans and animals: The present invention relates to a composition and a kit for the protection, treatment and repair of cartilage in humans and animal joints. The composition or kit contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. Preferably, the composition or kit contains avocado:soybean unsaponifiables... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080176932 - Pharmaceutical compositions containing baicalein and baicalin with synergistic effect in tumor treatment: e

20080176934 - Use of diosmetin compounds in the treatment and prevention of thrombotic pathologies: Use of diosmetin compounds in obtaining pharmaceutical compositions intended for the prevention and/or treatment of thrombotic pathologies and pathologies with a risk of thrombosis.... Agent: The Firm Of Hueschen And Sage

20080176936 - Classes of compounds that interact with integrins: A method of inhibiting or effecting the activity of an integral receptor which comprises contacting an integrin with a compound of formula I, or a pharmaceutically acceptable salt thereof; General Formula I Wherein the ring may be of any configuration; Z is sulphur, oxygen, CH2, NH, NRA or hydrogen, in... Agent: Morrison & Foerster LLP

20080176937 - Novel crystalline mycophenolate sodium polymorph and processes to manufacture same: The present invention includes the discovery of a novel polymorphic form of sodium mycophenolate (MPS) and processes for its formation. Furthermore, the present invention also includes a process to efficiently and cleanly convert the novel polymorphic form to known Form M2.... Agent: Ivor M. Hughes, Barrister & Solicitor, Patent & Trademark Agents

20080176938 - Modulation of pathogenicity: e

20080176939 - Compounds which inhibit beta-secretase activity and methods of use thereof: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.... Agent: Morrison & Foerster LLP

20080176940 - Photolabile compounds: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In one embodiment, the light is visible light, which is not detrimental to the viability... Agent: Wilmerhale/columbia University

20080176941 - Process for the preparation of polynuclear ferric hydroxide-saccaride complexes: The invention discloses a process for preparing a polynuclear ferric hydroxide-saccharide complex, including: adding an aqueous solution of an alkaline substance drop-wise into an aqueous solution of iron salt at a temperature of 5-20° C. until pH 6-8, collecting the polynuclear ferric hydroxide from the reaction mixture by a conventional... Agent: Workman Nydegger

20080176942 - Stabilized sulforaphane: A method of stabilizing sulforaphane is provided. The method includes contacting sulforaphane, or an analog thereof, and a cyclodextrin to form a complex between the sulforaphane, or analog thereof, and the cyclodextrin.... Agent: Nelson Mullins Riley & Scarborough, LLP

20080176943 - One part, solids containing decontamination blend composition: A one part, solids containing decontamination blend composition comprises a solid acetyl donor coated with a compound that protects it from hydrolysis, a peroxygen source, optionally a catalyst, optionally a surfactant, and optionally a buffer. The decontamination blend composition is generally in a dry powder, particle, etc form or in... Agent: Hudak, Shunk & Farine, Co., L.p.a.

20080176944 - Elongase genes and uses thereof: The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated fatty acids (i.e., “elongases”) and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma... Agent: Steven F. Weinstock Abbott Laboratories

20080176945 - Carboxilic acid amides provoking a cooling sensation: e

20080176946 - Formulations for cancer treatment: The present invention provides compositions of matter, kits, and methods for use in treating cancer and viral conditions. In particular the invention provides for pharmaceutical compositions containing nitrobenzamide compounds that have enhanced solubility in aqueous solutions.... Agent: Wilson Sonsini Goodrich & Rosati

20080176947 - Heterocyclic-substituted alkanamides useful as renin inhibitors: Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080176948 - Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic: A topical anesthetic for rapid local anesthesia is provided. The topical anesthetic includes an anesthetic, volatile and non-volatile solvents, and a thickener. In addition, a method is taught for applying the topical anesthetic to the face of a patient without occlusion. The anesthetic is applied topically to an area for... Agent: Paul D. Bianco Fleit Gibbons Gutman Bongini & Bianco Pl

20080176949 - Sertraline hydrochloride polymorphs: The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic... Agent: Steven J. Lee, Esq. Kenyon & Kenyon

20080176951 - Methods of treating gastrointestinary and genitourinary pain disorders: e

20080176950 - Treatments using venlafaxine:

20080176952 - Management of ophthalmologic disorders, including macular degeneration: A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inhibits, antagonizes, or short circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.... Agent: Foley Hoag, LLP Patent Group (w/huv Hmv)

20080176953 - Methods and compositions for treatment of ocular neovascularization and neural injury: Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.... Agent: Stout, Uxa, Buyan & Mullins LLP

20080176954 - Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected... Agent: Buchanan, Ingersoll & Rooney Pc

20080176955 - Combined administration of benzonatate and guaifenesin: Pharmaceutical compositions are provided containing a combination of benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof. Methods of using compositions comprising benzonatate and guaifenesin, or pharmaceutically acceptable salts thereof, provide relief from cough, pulmonary congestion or both. The compositions and methods provide relief to opiate-sensitive individuals, in particular, as well... Agent: Wilson Sonsini Goodrich & Rosati

20080176956 - Modified green tea polyphenol formulations: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080176957 - Preservative compositions comprising renewably-based, biodegradable 1,3-propanediol: Disclosed herein are preservative compositions comprising 1,3-propanediol, wherein the 1,3-propanediol in said composition has a bio-based carbon content of about 1% to 100%. In addition, it is preferred that the 1,3-propanediol be biologically-derived, and wherein upon biodegradation, the biologically-derived 1,3-propanediol contributes no anthropogenic CO2 emissions to the atmosphere.... Agent: Mccarter & English, LLP Basil S. Krikelis

20080176959 - Biodegradable polyphosphates complex for controlled release of bioactive substances and related methods: The present invention is directed to a biodegradable system for the controlled release of bioactive substances. This system comprises novel biodegradable and biocompatible polyphosphoesters that carry positive charges. Process for making these polyphosphoesters, compositions containing these polyphosphoesters and biologically active substances, articles and methods for delivery of drugs and genes... Agent: Greenberg Traurig LLP (la)

20080176958 - Cyclodextrin-based polymers for therapeutics delivery: The present invention relates to novel compositions comprising polymeric moieties covalently attached to therapeutic agents, wherein the therapeutic agent is attached to the polymeric moiety through a tether. By selecting from a variety of tether groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents.... Agent: Ropes & Gray LLP

20080176960 - Biodegradable biopolymers, method for their preparation and functional materials constituted by these biopolymers: A biodegradable biopolymer material consists of silk fibroin from domesticated silkworm; silk fibroin from wild silkworm; a composite material comprising silk fibroin from domesticated silkworm and silk fibroin from wild silkworm; or a composite material comprising either silk fibroin from domesticated silkworm or silk fibroin from wild silkworm and at... Agent: Arent Fox LLP

20080176964 - Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies: The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).... Agent: Alcon

20080176962 - Methods and compositions for identifying cellular genes exploited by viral pathogens: Methods and compositions for rapidly identifying CGEPs required for viral infection of mammalian cells are provided. Also provided are methods of inhibiting viral infection of mammalian cells by inhibiting the activity of one or more CGEPs (e.g., as identified in accordance with methods of the invention) in the cells. Aspects... Agent: Bozicevic, Field & Francis LLP

20080176961 - Phosphodiesterase acitvity and regulation of phosphodiesterase 1-b-mediated signaling in brain: The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32... Agent: Hoxie & Associates Llc

20080176963 - Treatment of brain disorders of the striatum: Regulation of striatal indirect pathway endocannabinoid-mediated long-term depression (eCB-LTD) is used to improve motor deficits of striatal-based brain disorders. In such treatment, a dopamine D2 receptor agonist is administered in conjunction with an inhibitor of endocannabinoid degradation. In some embodiments, the inhibitor of endocannabinoid degradation is a fatty acid amine... Agent: Bozicevic, Field & Francis LLP

  
07/17/2008 > patent applications in patent subcategories. cataloged by category listing

20080171687 - Compositions and methods for the preparation and administration of poorly water soluble drugs: Sterile, stable pharmaceutical formulations of poorly water-soluble drugs dissolved in dimethyl isosorbide, a water-miscible solvent, as well as methods for their preparation and administration.... Agent: Leydig Voit & Mayer, Ltd

20080171690 - Compositions and methods for the therapy and diagnosis of lung cancer: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides.... Agent: Seed Intellectual Property Law Group PLLC

20080171689 - Compositions and methods of treating disease with fgfr fusion proteins: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080171693 - Compounds that inhibit hsp90 protein-protein interactions with iap proteins: Disclosed herein are compounds that inhibit Hsp90 interactions with IAP proteins, such as Survivin, XIAP, cIAP1, or cIAP2, and methods for identifying and using such compounds.... Agent: Fish & Richardson PC

20080171691 - Inhibition of invasive remodelling: Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease.... Agent: Browdy And Neimark, P.l.l.c.

20080171688 - Recombinant vaccine from ge, gi, and gb proteins of the varicella-zoster virus for the treatment and prevention of multiple sclerosis: v

20080171692 - Substituted amides: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20080171695 - Insulin derivatives: The present invention is related to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of B chain or to an ε-amino group of a Lys residue present in the B chain of the parent insulin molecule via an amide bond... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080171694 - Pharmaceutical formulation comprising crystalline insulin and dissolved insulin: The invention provides a pharmaceutical formulation and a method for preparing the formulation.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080171696 - Pharmacodynamically enhanced therapeutic proteins: Compositions containing an N-linked oligosaccharide having little or no terminal sialic acid residues which is attached to a therapeutic protein that is bonded to a glycol polymer.... Agent: Avigenics, Inc.

20080171698 - Anti-hypertensive molecules and process for preparation thereof: The present invention relates to novel anti-hypertensive molecules. The present invention also provides a process for the preparation of novel antihypertensive molecules. The present invention particularly relates to the preparation of novel Angiotensin Converting Enzyme Inhibitors (ACEI) with prolonged activity. ACE inhibitors play an important role in Re -Angiotensin-Aldosteron system... Agent: Ladas & Parry LLP

20080171697 - Peptides having for example antiangiogenic activity and applications thereof in therapeutics: The invention relates to cyclised peptides corresponding to sequence SEQ ID No1: X1X2RGDX3FGX4X5LLFIHFX6IGSX7HSX8IX9, wherein: the letters without any numerical index correspond to amino acids defined by the single-letter international code; X1 is G or GG having an amino-terminal end which may or may not be free; X2 is either a... Agent: Nixon & Vanderhye, PC

20080171699 - Novel cyclic peptides: e

20080171701 - Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue... Agent: John P. White Cooper & Dunham LLP

20080171703 - Method of administering and using vegf inhibitors for the treatment of human cancer: A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and... Agent: Regeneron Pharmaceuticals, Inc

20080171702 - Novel gene and uses therefor: The present invention relates generally to a nucleic acid molecule which encodes a protein associated with the modulation of obesity, diabetes and metabolic energy levels. More particularly, the present invention is directed to a nucleic and a recombinant and purified naturally occurring protein encoded thereby and their uses in therapeutic... Agent: Morrison & Foerster LLP

20080171700 - Use of secretagogue for the teatment of ghrelin deficiency: The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080171704 - Composition and method for treating diabetes: The present invention comprises dosing regimens and formulations of islet cell neogenesis associated protein (INGAP) and INGAP Peptide. The formulation disclosed herein is shown have acceptable stability as a pharmaceutical composition. Further, the formulation is able to regenerate functional islets.... Agent: Lott & Friedland, P.A.

20080171705 - Methods of inducing and treating vascular disease: Animal testing, wherein the animals have disease state characteristics substantially equivalent to those found in humans, may be utilized to evaluate the efficacy of medical devices and/or therapeutic agents.... Agent: Philip S. Johnson Johnson & Johnson

20080171706 - Anti-adhesive compounds to prevent and treat bacterial infections: The present invention provides compounds and compositions capable of inhibiting the attachment of Gram-negative bacteria on a host epithelium. Accordingly, said compounds and compositions can for example be used for the manufacture of a medicament to treat urinary, lung and gastrointestinal infections caused by said Gram-negative bacteria... Agent: Trask Britt

20080171707 - Use of an onion extract for making a composition to control weight gain: The invention concerns the use of an onion extract comprising 20 wt. % to 40 wt. % of polyphenols of the flavonol family, said onion extract having the following composition characteristics, expressed in weight relative to the total extract dry weight: 60 wt. % to 90 wt. % of the... Agent: Young & Thompson

20080171708 - Analgesic and anti-inflammatory compositions and methods with flavonoid glycoside-type compounds: The present invention relates to pharmaceutical compositions containing certain flavonoid glycoside-type compounds that have been shown in the present invention to be therapeutically useful, including useful as analgesics and anti-inflammatories for the treatment and management of pain and inflammatory conditions. Methods for the therapeutic uses of such compounds and pharmaceutical... Agent: Hall, Vande Sande & Pequignot, LLP

20080171709 - Pharmaceutical composition comprising an antiviral agent, an antitumoral agent or an antiparasitic agent, and an active agent selected among carveol, thymol, eugenol, borneol,and carvacrol: The invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone and beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is antitumoral. The invention is for use... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080171717 - Double-stranded synthetic oligonucleotides useful for inducing apoptosis of osteoclasts for the treatment of osteopenic pathologies: The invention relates to a synthetic double-stranded oligonucleotide capable of modifying the molecular phenotype of osteoclasts and increasing the expression of the oestrogen alpha receptor gene. Pharmaceutical compositions comprising the oligonucleotide according to the invention are also described, as well as therapeutic applications of that oligonucleotide, in particular for the... Agent: Sughrue Mion, PLLC

20080171718 - Methods and compositions for treating cancer using bcl-2 antisense oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents: Methods and compositions are provided for treating cell-proliferative related disorders such as cancer. Methods of inhibiting the growth of cancer cells comprise contacting the cancer cells with a Bcl-2 antisense oligomer; contacting the cancer cells with a tyrosine kinase inhibitor; and contacting the cancer cells with a cytotoxic chemotherapeutic agent.... Agent: Diehl Servilla LLC

20080171715 - Methods and compositions involving mirna and mirna inhibitor molecules: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors... Agent: Fullbright & Jaworski L.L.P.

20080171711 - Mrna mixture for vaccinating against tumoral diseases: The present invention relates to a mixture which contains mRNA for vaccination, wherein at least one mRNA contains a domain which codes for at least one antigen from a tumor and at least one further mRNA contains a domain which codes for at least one immunogenic protein (polypeptide). The invention... Agent: Connolly Bove Lodge & Hutz LLP

20080171716 - Nucleic acid modulation of toll-like receptor-mediated immune stimulation: The present invention provides methods of modulating the activation of certain Toll-like receptors (TLRs) such as TLR7/8 using chemically modified nucleic acid molecules. The present invention also provides methods of using such modified nucleic acid molecules to treat diseases or disorders associated with TLR7/8 activation such as systemic lupus erythematosus.... Agent: Townsend And Townsend And Crew, LLP

20080171719 - Rnai-mediated inhibition of aquaporin 1 for treatment of iop-related conditions: RNA interference is provided for inhibition of aquaporin 1 (AQP1) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon

20080171712 - Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.... Agent: Keown & Zucchero, LLP

20080171713 - Substances for preventing and treating autoimmune diseases: A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the... Agent: Sheldon Mak Rose & Anderson PC

20080171714 - Substances for preventing and treating autoimmune diseases: A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the... Agent: Sheldon Mak Rose & Anderson PC

20080171710 - The redox/fyn/c-cbl pathway: Methods and compositions related to a novel cellular pathway, the redox/Fyn/c-Cbl pathway, include a variety of aspects. Provided herein are agents that selectively interrupt the pathway and methods of using the same. Also provided are screening methods used to identify a pro-oxidation toxicant or other agents and stimuli that affect... Agent: Fish & Richardson P.C.

20080171720 - Nutritional supplement for hiv patients: The present invention relates to a nutritional product for HIV patients. More specifically the invention relates to a nutritional composition that provides carefully selected nutritional ingredients including oligosaccharides and cysteine and/or a source of cysteine specifically supporting HIV patients with nutritionally related symptoms. This invention also relates to the manufacture... Agent: Foley And Lardner LLP Suite 500

20080171721 - Halogenated alkyl di- and trisaccharides, pharmaceutical formulations, diagnostic kits and methods of treatment: The present invention relates to a novel family of alkylated halogenated di- and trisaccharides which exhibit pharmaceutical efficacy in the areas of permeation enhancers, anti-microbial effects, anti-fugal effects, facilitation of diagnostic procedures. The invention further includes methods of treatment and diagnostic kits.... Agent: Owen J. Bates

20080171722 - Heparin oligosaccharides: The present invention provides composition and methods for the synthesis of low molecular weight heparins and heparinoids. The present invention also provides compositions having substantially homogenous populations of desired heparin molecules, or molecules useful in the synthesis of heparin oligosaccharides.... Agent: Casimir Jones, S.c.

20080171723 - Boronic acid aryl analogs: The present invention relates to novel boronic acid aryl derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic acid aryl... Agent: Townsend And Townsend And Crew, LLP

20080171724 - Phosphonate derivatives of mycophenolic acid: Phosphorus substituted mycophenolate oxime derivatives with anti-cancer, anti-viral, anti-inflammatory anti-tissue/organ transplant rejection properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit tumor growth, viral growth, inflammation, and tissue/organ transplant rejection and/or are useful therapeutically for the treatment or prevention of cancer, viral infection, inflammation... Agent: Viksnins Harris & Padys Pllp

20080171725 - Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for... Agent: Fulbright & Jaworski L.L.P.

20080171726 - Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for... Agent: Fulbright & Jaworski L.L.P.

20080171727 - Methods of treating acne: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.... Agent: Irving N. Feit, Esq. Hoffmann & Baron, LLP

20080171728 - Efficient process for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone: m

20080171729 - Use of a steroid for enhancement of skin permeability: A method for enhancing skin permeability by administration of a tetracyclic compound and improved methods for treatment of disorders by administration of a tetracyclic compound and a pharmaceutically active compound.... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20080171730 - Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes and vascular and renal disorders: Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include... Agent: The Mccallum Law Firm, P. C.

20080171731 - Prevention of ovarian cancer by administration of a vitamin d compound: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject.... Agent: Jenner & Block, LLP

20080171734 - Chemical compounds: wherein R1, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases... Agent: Morgan Lewis & Bockius LLP

20080171733 - Amino-tetrazoles analogues and methods of use: e

20080171732 - New pyridine analogues ix 519:

20080171735 - Succinoylamino benzodiazepines as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080171736 - Treatment of alzheimer's disease and mild cognitive impairment using gnrh-i analogs and one or more of acetylcholinesterase inhibitors and nmda receptor antagonists: Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease and Mild Cognitive Impairment (MCI) include administration of gonadotropin-releasing hormone analogs in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080171737 - Cyclic sulfonamide derivatives and methods of their use: or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behaviorial disorder, cognitive disorder, diabetic neuropathy, pain, and... Agent: Wyeth Patent Law Group

20080171738 - Treatment of breast cancer: A method of treating a patient with breast cancer includes administering to the patient a breast cancer cell proliferation-inhibiting amount of a methylol-containing compound such as taurolidine, taurultam or a mixture thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080171739 - Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals: in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080171740 - Chemical compounds: The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to a chemokine receptor, and which affect the binding of a natural ligand or chemokine to a receptor, such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080171741 - Heterocyclic amide compounds useful as kinase inhibitors: e

20080171742 - 4-(pyrid-2-yl) amino substituted pyrimidine as protein kinase inhibitors: A compound of formula (I): wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm-blooded animal such as man.... Agent: Astrazeneca R&d Boston

20080171743 - Transcutaneous immunostimulation: c

20080171744 - Compounds and method for treatment of cancer: The present invention is directed to a compound of Formula I: and/or a pharmaceutically-acceptable salt, hydrate, solvate, tautomer, optical isomer, or combination thereof, a composition comprising the thiosemicarbazone, a method of administration thereof, and use thereof to treat a cancer.... Agent: Swanson & Bratschun, L.L.C.

20080171746 - Method for preventing cardiovascular diseases: The invention relates to a method for selecting COX-2 selective NSAIDs which have a salutary therapeutic profile. The invention further relates to the use of these selected COX-2 selective NSAIDs in the treatment of certain diseases. The invention yet further relates to combinations comprising COX-2 selective NSAIDs and the use... Agent: Nath & Associates PLLC

20080171745 - Methods relating to the treatment of fibrosis: The invention provides α-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate... Agent: Nixon Peabody LLP - Patent Group

20080171747 - Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions: e

20080171748 - Substituted piperidines: Substituted piperidines of formulae (I) and (II) with the substituent definitions as explained in the specification. The compounds are suitable in particular as renin inhibitors and are highly potent.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080171749 - 1-phenyl-1,2-diaminoethane derivatives as modulators of the chemokine receptor activity: wherein the groups A, R1, R2 and Ra through Rj have the meanings given in the claims and specification, for the preparation of a medicament for the treatment and/or prevention of a disease, wherein the activity of a CCR3 receptor is involved and to novel compounds of formula (I), wherein... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080171750 - Modulation of neurogenesis with use of modafinil: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of modafinil, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of... Agent: Townsend And Townsend And Crew, LLP

20080171751 - Triazole compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080171752 - 5-ht1a receptor subtype agonist: e

20080171753 - Carbamoyl-substituted spiro derivative: (wherein R6 represents a lower alkyl, etc; and R7 and R8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful... Agent: Merck And Co., Inc

20080171754 - Certain pyrazoline derivatives with kinase inhibitory activity: The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20080171756 - N-substituted glycine derivatives: prolyl hydroxylase inhibitors: e

20080171755 - Pyrimidinylpyrazoles as tgf-beta inhibitors: The invention is based on the discovery that compounds of formula (I) possess high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. The invention features a compound of formula (I) and uses thereof: formula (I).... Agent: Miller, Canfield, Paddock And Stone, PLC

20080171757 - Methods to identify inhibitors of cell sickling: The invention relates to methods of screening for inhibitors of diseases or biological processes that involve peptide or protein polymerization. Included in the methods of the invention are methods to identify inhibitors of deoxyhemoglobin S polymerization. Also included in the invention are diagnostic and therapeutic methods.... Agent: Edwards Angell Palmer & Dodge LLP (client Reference No. 47992)

20080171758 - Compounds and methods for the treatment of cancer: (−)-(2S,4S)-1-(2-Hydroxymethyl-1,3-dioxolan-4-yl)cytosine (also referred to as (−)-OddC) or its derivative and its use to treat cancer in animals, including humans.... Agent: Henry D. Coleman

20080171759 - Spiropiperidine glycinamide derivatives: wherein X, Y and R1 to R10 are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080171760 - Spiropiperidine glycinamide derivatives: wherein X, Y and R1 to R10 are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080171761 - Substituted spirochromanone derivatives: e

20080171762 - Treatment of pain with naloxone: A method of effectively treating nociceptive pain involves administering to a human or animal in need of relief from nociceptive pain a therapeutically effective amount of naloxone intranasally, intravenously, by inhalation, transdermally, or orally. Pain associated with fibromyalgia, arthritis, surgical procedures, etc. can be effectively treated.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20080171765 - Aniline or phenol mustards linked to dna-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents: New aniline or phenol N-mustards linked to DNA-affinity carriers (such as 9-anilinoacridines, acridines and quinolines), aminobenzamides or aminophenol ethers by a urea, carbamic acid, carbanic acid ester, hydrazineurea, hydrazinecarbamic acid ester, phenoxyurea, phenoxycarbamic acid ester linkage with improved chemical stability and anti-tumor therapeutic efficacy are provided.... Agent: Cohen, Pontani, Lieberman & Pavane

20080171763 - Compounds and methods for treatment and prevention of diseases: A prodrug compound of a rapamycin analog and methods for inhibiting, treating, and preventing mammalian diseases.... Agent: Workman Nydegger

20080171764 - Methods for preventing, managing, and reversing disease caused by inflammation mediated vascular lesions: Methods for preventing, managing and reversing disease caused by inflammation mediated vascular lesions may utilize agents that bind to FKBP 12 and inhibit mTOR cascade.... Agent: Philip S. Johnson Johnson & Johnson

20080171766 - Novel method: A method for the treatment or prophylaxis of an infection in a mammal, said infection caused by an anti-microbial resistant bacteria, comprising, administering, to the mammal a pleuromutilin derivative is disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080171767 - Acetamide compounds as fungicides: Compounds of the general formula (I); wherein the substituents are as defined in claim 1, are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080171768 - Pharmaceutical composition containing an anti parasitic agent and active ingredient selected from carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, or beta-ionone: The present invention relates to a pharmaceutical composition comprising at least one first active therapeutic substance selected among carveol, thymol, eugenol, borneol, carvacrol, alpha-ionone, beta-ionone, as well as isomers, derivatives and mixtures thereof, and comprising at least one second active therapeutic substance that is an antiparasitic agent, in particular, an... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080171769 - Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders: e

20080171770 - Compounds:

20080171772 - 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity: and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases,... Agent: Allergan, Inc.

20080171771 - New compounds 391: d

20080171773 - Factor xa inhibitor: (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide} pharmaceutical compositions, methods and methods of using the compound or pharmaceutical compositions thereof to treat diseases characterized by abnormal thrombosis in mammals. Crystalline form of (R)-5-Methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chloro-phenyl)amide]5-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}... Agent: Pfizer Inc.

20080171774 - Nicotinanilides, method for production thereof and agents comprising the same for prevention of fungal pests: )

20080171775 - Ramipril-amlodipine salt: The present invention relates to a ramipril-amlodipine salt.... Agent: Wilson Sonsini Goodrich & Rosati

20080171776 - 6-oxazol-4-ylmetholmethoxy-alko-alkoxymethyl substituted benzoic acid derivatives forming peroxisome proliferator - activated receptor (ppar) ligands, process for their preparation and methods of use thereof: e

20080171777 - Biaryl substituted triazoles as sodium channel blockers: Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and... Agent: Merck And Co., Inc

20080171778 - N3 alkylated benzimidazole derivatives as mek inhibitors: and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such... Agent: Hogan & Hartson LLP

20080171779 - Use of 5-ht6 antagonists to prevent relapse into addiction: A novel use of compounds and pharmaceutically acceptable salts thereof, which are 5-HT6 antagonists, are disclosed. In one embodiment, the invention relates to the use of these compounds or pharmaceutical compositions comprising these compounds for preventing relapse into addiction, for example, relapse into addiction to substances of abuse, including opiates,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080171780 - Process for crystallization of ramipril and preparation of a hydrated form thereof: The present invention relates to a novel method for obtaining (2S,3aS,6aS)-1-[(S)-2-[[(S)-1-(ethoxycarbonyl)-3-phenylpropyl]-amino]propanoyl]octahydro cyclopenta[b]pyrrole-2-carboxylic acid, viz. Ramipril(I) in high optical purity, free of other stereoisomers, and in high bulk density. The present invention also relates to a novel hydrated form of Ramipril(I) and a process for preparation thereof.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080171781 - Hemodynamics improving agent: Agents which contains a serotonin derivative as an active ingredient are effective for improving hemodynamics and for preventing or improving deterioration of hemodynamics associated with aging and progression of cardiovascular diseases.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080171783 - Compositions and methods for treating hyperproliferative disease: The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha... Agent: Darby & Darby P.C.

20080171782 - Inhibitors of isoprenylcysteine carboxyl methyltransferase: The present invention relates, in general, to isoprenylcysteine carboxylmethyltransferase (Icmt) and, in particular, to inhibitors of Icmt and to methods of disease treatment using same.... Agent: Nixon & Vanderhye, PC

20080171784 - Methods for the stabilization of atorvastatin: Stabilization of the pharmaceutical active solid substance atorvastatin alone or in a mixture with other solid substances embedded in a gaseous mixture is carried out in such a manner that in the surrounding gaseous mixture a partial pressure of oxygen of at most 2 kPa, preferably less than 1 kPa,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080171785 - Dosing regimens for ion channel modulating compounds: Dosing regimens, routes of administration and methods for the treatment or prevention of arrhythmias are disclosed. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early after depolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof... Agent: Seed Intellectual Property Law Group PLLC

20080171786 - Substituted [(phenylethanoyl)amino]benzamides: The invention relates to substituted [(phenylethanoyl)amino]benzamides and methods for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of inflammatory disorders such as, for example, cutaneous, respiratory tract and cardiovascular disorders such as, for example, arteriosclerosis and coronary heart disease.... Agent: Bayer Health Care LLC

20080171787 - Colchicine neoglycosides and methods for their synthesis and use: Colchicine neoglycosides, method for their synthesis and methods for their use are disclosed. The invention provides analogs of colchicine glycosylated to include a sugar moiety on a colchicine scaffold that is generally unglycosylated in nature. The colchicine neoglycosides disclosed herein are shown to have cytotoxic effects equivalent to at least... Agent: Quarles & Brady LLP

20080171788 - Medicament for irritable bowel syndrome: The pharmaceutical composition of the invention is useful as a drug which is excellent in the therapeutic effect on IBS and shows lessened side effects occurring in the existing remedies for IBS, because it showed good pharmacological actions in comparison with the case of independently using a 5-HT2B receptor antagonist... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080171789 - Catechol protected levodopa diester prodrugs, compositions, and methods of use: Catechol protected levodopa diester prodrugs pharmaceutical, compositions comprising catechol protected levodopa diester prodrugs, and methods of using such prodrugs and pharmaceutical compositions for treating diseases such as Parkinson's disease are provided.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080171790 - Fatty acids-systemic lipid solubilizers conjugates: A pharmacological compound characterized by the conjugation of a fatty acid such as butyric, caproic, caprylic, lauric, myristic, palmitic, stearic, arachidic, behenic, oleic, linoleic, alpha-linolenic, arachidonic, eicosapentaenoic, docosahexaenoic acid, euric acid with Hyodeoxycholic acid or other systemic biocompatible lipid solubilizer/detergent compounds, as opposed to biocompatible lipid solubilizers/detergents sequestered in the... Agent: Giorgio Zadini

20080171791 - Compositions and method for losing weight: Methods and compositions for assisting in human weight loss. In a preferred embodiment, the administration of branched-chain amino acids and fatty acids to a subject at a level that provides approximately a two and a half percent (2.5%) reduction in weight over a one-week period.... Agent: Patricia Mcqueeney Mdr Fitness Corp.

20080171792 - Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders: A highly concentrated preparation of sodium 4-phenylbutyrate in an aqueous medium as an alternative for present high dosage therapeutic treatments of certain disorders is provided, specifically for the treatment of spinal muscular atrophy (SMA), central nervous system (CNS) cancer, myelodysplastic syndrome (MS), acute leukemia, glioblastoma multiforme, amyotrophic lateral sclerosis (ALS),... Agent: King & Spalding LLP

20080171793 - Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses therefor: Provided herein are bioactive agents comprising a compound that inhibits the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR) and that is linked to a macromolecule that interacts with a cell that expresses CFTR. The bioactive agents described herein are useful for treating diseases, disorders, and sequelae... Agent: Seed Intellectual Property Law Group PLLC

20080171794 - Humectant composition: in which R is an alkylene group having 2 to 5 carbon atoms which may be substituted with at least one member selected from the group consisting of a methyl group and a hydroxyl group, and n is an integer of 1 to 3. The humectant composition of the present... Agent: Fitzpatrick Cella Harper & Scinto

20080171795 - Novel inter and intra multilamellar vesicular composition: The present invention is related to the development of a novel inter and intra multilamellar vesicular composition containing an antipsoriatic drug dithranol. The exquisitely structured mesophase made up of saturated phospholipids (which have an inherent antioxidant property and protect the lipid soluble molecules) at the micro range level improve the... Agent: Marshall, Gerstein & Borun LLP

20080171796 - Novel macrocyclic musk: e

20080171797 - Methods of modulating mitochondrial nad-dependent deacetylase: The present invention provides methods for identifying agents that modulate a level or an activity of a mitochondrial NAD-dependent deacetylase polypeptide, as well as agents identified by the methods. The invention further provides methods of modulating mitochondrial NAD-dependent deacetylase activity in a cell. The invention further provides methods of modulating... Agent: Bozicevic, Field & Francis LLP

  
07/10/2008 > patent applications in patent subcategories. cataloged by category listing

20080167217 - Aryl ketone compounds and compositions for delivering active agents: P

20080167216 - Treatment of parkinson's disease and related disorders: Described herein are compositions and methods for the treatment of Parkinson's disease (PD) and/or to protect dopaminergic nigrostriatal neuronal cell bodies from 6-OHDA-induced neurotoxicity in a mammal. In various embodiments of the invention, the dopaminergic neuron differentiation factor sonic hedgehog (Shh) and/or its downstream transcription factor target Gli-1 are used... Agent: Davis Wright Tremaine LLP/los Angeles

20080167218 - Pegylated g-csf polypeptides and methods of producing same: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to... Agent: Maxygen, Inc. Intellectual Property Department

20080167219 - Recombinant human factor ix and use thereof: The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.... Agent: Wpat, PC Intellectual Property Attorneys

20080167220 - Methods for selectively inhibiting janus tyrosine kinase 3 (jak3): Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting... Agent: Conley Rose, P.C. David A. Rose

20080167233 - Active complex of alpha-lactalbumin (hamlet) and cofactor: The use of a biologically active complex of α-lactalbumin, selected from HAMLET (human α-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous... Agent: Nixon & Vanderhye, PC

20080167238 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080167239 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080167240 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080167227 - Anti-angiogenic and anti-tumor properties of matin and other laminin domains: A protein with anti-angiogenic properties is disclosed.... Agent: Nixon Peabody, LLP

20080167232 - Anti-angiogenic and anti-tumor properties of vascostatin and other indogen domains: A protein with anti-angiogenic properties is disclosed.... Agent: Nixon Peabody, LLP

20080167243 - In vivo incorporation of unnatural amino acids: The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.... Agent: Quine Intellectual Property Law Group, P.C.

20080167229 - Inhibitors of usp1 deubiquitinating enzyme complex: The invention provides compositions and methods used to inhibit USP1 deubiquitinase activity and to identify new inhibitors of USP1 deubiquitinase. The inhibitors can be used to treat or prevent cancer, bone marrow failure, and damage to cells or DNA resulting from genotoxic agents such as antineoplasic agents, including chemotherapeutic agents... Agent: Edwards Angell Palmer & Dodge LLP

20080167235 - Methods and compositions for healing and repair of articular cartilage: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in... Agent: Wyeth/finnegan Henderson, LLP

20080167236 - Methods and compositions for healing and repair of articular cartilage: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in... Agent: Wyeth/finnegan Henderson, LLP

20080167237 - Methods and compositions for healing and repair of articular cartilage: Methods and compositions are provided for the treatment of articular cartilage defects and disease involving the combination of tissue, such as osteochondral grafts, with active growth factor. The active growth factor is preferably a composition containing at least one bone morphogenetic protein and a suitable carrier. The method results in... Agent: Wyeth/finnegan Henderson, LLP

20080167230 - Methods and compositions for treating or preventing lesions of the respiratory epithelium: This invention features methods of treating lesions of the airway epithelium by local or systemic administration of intestinal trefoil peptides. The intestinal trefoil peptide can be administered either alone or in combination with one or more therapeutic agents.... Agent: Clark & Elbing LLP

20080167223 - Methods and compositions for using tsh in the inhibition of tnf activity: The present invention is direct to methods and compositions for inhibiting TNF activity. In particular it has been found that TSH may be used to inhibit the activity of TNF. Methods and compositions for exploiting this finding are described.... Agent: Marshall, Gerstein & Borun LLP

20080167231 - Modified corticotropin releasing factor peptides and uses thereof: The present invention relates to compounds comprising modified corticotrophin releasing factor peptide and specifically urocortin and urocortin-related peptides, modified derivatives thereof, and conjugates of such modified peptides and derivatives to serum components, preferably serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group, which is... Agent: Lowrie, Lando & Anastasi, LLP

20080167241 - Mu-1, member of the cytokine receptor family: Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.... Agent: Fitzpatrick Cella (wyeth)

20080167245 - Novel metastasis suppressor gene on human chromosome 8: An isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding the metastasis suppressor gene located at p21-p12 on chromosome 8 of a human (Tey 1), a variant Tey 1, or a fragment of either of the foregoing comprising at least 455 contiguous nucleotides; an isolated or... Agent: Leydig, Voit & Mayer, Ltd.

20080167225 - Repair of larynx, trachea, and other fibrocartilaginous tissues: Provided herein are methods and devices for inducing the formation of functional replacement nonarticular cartilage tissues and ligament tissues. These methods and devices involve the use of osteogenic proteins, and are useful in repairing defects in the larynx, trachea, interarticular menisci, intervertebral discs, ear, nose, ribs and other fibrocartilaginous tissues... Agent: Ropes & Gray LLP

20080167228 - Screening assay for the identification of inhibitors of macrophage migration inhibitory factor: The present invention encompasses assays to identify compounds that inhibit the enzymatic activity of MIF which catalyzes the tautomerization of MIF-substrates, such as D-dopachrome to DHICA. In general, the assay is conducted in vitro by adding, mixing or combining MIF and a suitable substrate in the presence or absence of... Agent: Law Office Of John K. Pike, PLLC

20080167226 - Stable formulation of modified glp-1: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080167242 - Toll-like receptor agonists and antagonists and methods of use thereof: The present disclosure relates to compositions and methods of modulating inflammatory and immune responses through binding of SAA to TLR2 in a subject (e.g., human, non-human primate, rodent, etc.), and compositions and methods for screening TLR2 agonists and antagonists. In the studies described herein, a potential role of SAA in... Agent: Akerman Senterfitt

20080167222 - Use of growth hormone releasing factor analogs in treating patients suffering from wasting: The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.... Agent: Merchant & Gould PC

20080167234 - Use of hmgb fragments as anti-inflammatory agents: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080167244 - Use of il-28 and il-29 to treat cancer and autoimmune disorders: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as... Agent: Zymogenetics, Inc. Intellectual Property Department

20080167224 - Variants of the nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and their use: Variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use are disclosed. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF (SEQ ID NO:2) and these substitutions... Agent: Bell, Boyd, & Lloyd LLP

20080167246 - Ophthalmic and contact lens solutions containing peptides as preservative: A contact lens solution comprising 0.001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: D4E1, D2A21, and P-113; and at least 0.0001 weight percent of a preservative, and where the concentration of chloride in said solution is less than 0.2 percent by weight.... Agent: Hiscock & Barclay, LLP

20080167247 - Peptide inhibitors of protein kinase c: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.... Agent: Perkins Coie LLP

20080167248 - Anti-aging effects of substance p: Substance P or its analogs can be administered to humans to reverse or retard the course of various biological processes related to aging in adults. Reversal or retardation can be observed in hair color, muscle or joint pain, memory loss, sleep pattern, and visual accommodation.... Agent: Banner & Witcoff, Ltd.

20080167250 - Method for induction and enhancement of apoptosis in tumor cells: The present invention relates to methods for inducing and enhancing apoptosis in pathogenic cells. In particular, the present invention relates to the use of GnRH II antagonists for inducing and enhancing apoptosis of specific types of tumor cells, i.e. breast cancer and malignant melanoma as well as gynaecological cancers like... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080167249 - Protective factors against inflammation, burns and noxious stimuli: Peptide factors isolated from skin following exposure to chemical or thermal injury and treatment with iodine preparations are capable of reducing or ameliorating the extent of injury when administered to other animals. Specific peptides, including fragments of histone H2A and fibrinopeptide A, and preferred derivatives of these peptides are disclosed.... Agent: Winston & Strawn LLP Patent Department

20080167251 - Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth: The present invention describes the use of angiotensin-(1-7) peptide as an anti-cancer therapeutic. Thus, in one embodiment, the present invention comprises a composition to inhibit the growth of cancer cells in an individual comprising a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit cancer cell growth... Agent: Kilpatrick Stockton LLP

20080167252 - Method for treating a patient undergoing chemotherapy: The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080167253 - Monocyte locomotion inhibitory factor: The invention relates to an anti-inflammatroy oligopeptide which can be obtained from the microorganism Entamoeba histolytica or synthesized by known methods. The oligopeptides are useful in treating inflammatory diseases when formulated in pharmaceutical compositions for administration to patients.... Agent: Rissman Jobse Hendricks & Oliverio, LLP

20080167254 - Triterpenes derivatives and uses thereof as antitumor agents or anti-inflammatory agents: e

20080167255 - 4-biarylyl-1-phenylazetidin-2-ones:

20080167261 - Altered recombinases for genome modification: The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also... Agent: Manuel F. De La Cerra

20080167256 - Cancer therapy via the inhibition of skp-2 expression: The present invention is to provide: a double-stranded RNA (siRNA) capable of suppressing expression of Skp-2 gene, a double-stranded RNA expression cassette capable of expressing a double-stranded RNA, a double-stranded RNA expression vector containing a double-stranded RNA expression cassette, and highly safe therapeutic drug and therapy specific to cancers such... Agent: Morgan & Finnegan, L.L.P.

20080167259 - Materials and methods for detecting interaction of cftr polypeptides: The subject invention concerns materials and methods for detecting the interaction of CFTR proteins. In one embodiment, the method can be used to determine whether one CFTR polypeptide interacts with a second CFTR polypeptide. The subject invention also concerns materials and methods for screening for drugs or compositions that can... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080167264 - Materials and methods to inhibit hodgkin and reed sternberg cell growth: Materials and methods are disclosed for modulating proliferation of cell types associated with Hodgkin's disease through inhibition of IL-13 and components in IL-13 associated signal transduction pathways. Methods to identify inhibitors, compositions comprising the inhibitors, and methods using the inhibitors to treat Hodgkin's disease are also disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080167262 - Methods and compositions for diagnosing and treating prostate cancer: The present invention relates to compositions and methods for cancer research, diagnosis, and treatment, including but not limited to, cancer markers. In particular, the present invention relates to BRCA1 markers for prostate cancer.... Agent: Casimir Jones, S.c.

20080167263 - Methods for modulating the efficacy of nucleic acid based therapies: Covalently reactive antigen analogs are disclosed herein. The antigens of the invention may be used to stimulate production of catalytic antibodies specific for predetermined antigens associated with particular medical disorders. The antigen analogs may also be used to permanently inactivate endogenously produced catalytic antibodies produced in certain autoimmune diseases as... Agent: Dann, Dorfman, Herrell & Skillman

20080167265 - Modulation of fr-alpha expression: Disclosed herein are compounds, compositions and methods for modulating the expression of FR-alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.... Agent: Knobbe, Martens, Olson & Bear, LLP

20080167260 - Nucleic acid sequences encoding peptides with utrophin spectrin-like repeats: The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides... Agent: Casimir Jones, S.c.

20080167257 - Oligonucleotide-containing pharmacological compositions and their use: The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20080167258 - Trans-excision-splicing ribozyme and methods of use: A group I intron-derived ribozyme which binds RNA in trans, excises an internal segment from within the RNA, and splices the remaining 5′ and 3′ ends of the RNA back together (the trans-excision-splicing reaction) is disclosed. The excised segment can be as long as 28 nucleotides, or more, and as... Agent: Mcdermott Will & Emery LLP

20080167266 - Process for preparing an iron saccharose complex: (b) the acidity of the reaction mixture is then raised to a value in the range 10<pH<12 and the reaction mixture is heated until the desired iron-sucrose complex has completely formed, and the iron-sucrose complex formed is then precipitated by mixing with a suitable water-miscible solvent, the iron-sucrose complex being... Agent: Hammer & Hanf, PC

20080167267 - Agent for drug clearance and accelerator for drug clearance: An agent for eliminating a drug and an accelerator for eliminating a drug which comprise hyaluronic acid or a salt thereof.... Agent: Sughrue-265550

20080167268 - Particulate beta-glucan compositions for regulating dendritic cells: Particulate β-glucan is administered at either a low concentration range or a high concentration range to affect cytokine secretion. At the high concentration range, particulate β-glucan induces secretion of inflammatory cytokines that enhance antigen presentation by dendritic cells and T cell expansion. Conversely, at the low concentration range, particulate β-glucan... Agent: Bioplymer Engineering, Inc. Dba Biothera, Inc.

20080167269 - Hydrolysis resistant organomodified silylated ionic surfactants: r

20080167270 - Anti-infective phosphonate analogs: The invention is related to phosphorus substituted anti-infective compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20080167221 - Heterocarpine, a plant-derived protein with anti-cancer properties: The invention relates to a plant-derived protein with anti-cancer properties which binds the human growth hormone-releasing hormone (hGHRH). Said protein, which is obtained from the Pilocarpus Heterophyllus plant, is particularly adapted for preparing a medicament that is intended for the treatment of cancers for which growth is dependant on the... Agent: Hedman & Costigan P.C.

20080167271 - Pharmaceutical compositions comprising a bisphosphonate compound: The present invention relates to pharmaceutical compositions comprising a bisphosphonate compound.... Agent: Foley And Lardner LLP Suite 500

20080167272 - Thalidomide metabolites and methods of use: The present invention concerns certain hydrolytic thalidomide metabolites, combinations thereof with other anti-neoplastic compounds and their use in the treatment of solid tumours.... Agent: Edwards Angell Palmer & Dodge LLP

20080167273 - 7,8 and 9-substituted tetracycline compounds: 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described.... Agent: Lahive & Cockfield, LLP

20080167274 - Composition containing progestin, phytoestrogen and vitamin d: A composition comprising a progestin, a phytoestrogen compound, and a Vitamin D compound. The phytoestrogen is preferably an isoflavone compound selected from the group consisting of daidzein, genistein, and glycitein and their conjugated forms. The progestin is preferably selected from the group consisting of norgestimate in the range of 0.18-0.25... Agent: Jenner & Block, LLP

20080167275 - Composition containing progestin, phytoestrogen, estrogen and vitamin d compound: A composition comprising a progestin, a phytoestrogen compound, an estrogen, and a Vitamin D compound. The phytoestrogen is preferably an isoflavone compound selected from the group consisting of daidzein, genistein, and glycitein and their conjugated forms. The progestin is preferably selected from the group consisting of norgestimate in the range... Agent: Jenner & Block, LLP

20080167276 - Pharmaceutical product containing progestin, genistein, and vitamin d compound: A pharmaceutical product comprising multiple daily sequential dosages, said product comprising a progestin, genistein, and an estrogen, and optionally a Vitamin D compound. The estrogen is selected from the group consisting of estrone, estrone sulfate, estrone sulfate piperazine salt, estradiol and estriol, and their esters, mestranol, conjugated equine estrogen, esterified... Agent: Jenner & Block, LLP

20080167277 - Methods of treating skin disorders with caffeic acid analogs: Methods of treating skin diseases such as plaque psoriasis and inverse psoriasis include topical application of one or a combination of caffeic acid phenethyl ester, caffeic acid benzyl ester, and analogs thereof as an active agent. A pharmaceutical composition containing the active agent may further include a cell differentiating agent... Agent: Patterson & Sheridan, L.L.P.

20080167278 - Composition containing progestin, phytoestrogen and estrogen: A composition comprising a progestin, a phytoestrogen compound, and an estrogen. The phytoestrogen is preferably an isoflavone compound selected from the group consisting of daidzein, genistein, and glycitein and their conjugated forms. The progestin is preferably selected from the group consisting of norgestimate in the range of 0.18-0.25 mg, levonorgestrel... Agent: Jenner & Block, LLP

20080167280 - Enhanced drug delivery in transdermal systems: A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a drug that includes a parent drug and a prodrug; and a pharmaceutically acceptable carrier, wherein the parent drug and prodrug are individually present in an amount sufficient for a pharmacological effect. In a preferred... Agent: Foley And Lardner LLP Suite 500

20080167279 - Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium: The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer. Enhanced HRT and OCP regimens and formulations are also disclosed.... Agent: Jenner & Block, LLP

20080167281 - Combination otic formulation: A therapeutic composition and methods for the treatment and prevention of otic disorders in humans and animals comprising an analgesic agent, an anesthetic agent, a combination of an astringent and an anti-infective are disclosed. The composition and method provides for contacting the tympanic membrane without substantially penetrating the tympanic membrane.... Agent: Hutchison Law Group PLLC

20080167282 - Use of inhibitors of steroid activity for the treatment of substance related disorders: The invention concerns the use of one or more steroid activity inhibitors, namely androgens, such as, for example, testosterone, for the treatment of disorders related to, or resulting from use of, or induced by substances or induced by intoxication from substances or abstinence from substances, mental disorders induced by substances,... Agent: Arent Fox LLP

20080167283 - Nandrolone 17 beta-carbonates: Disclosed are compounds of the formula (I) wherein R is C1-C30 alkyl, which may be optionally further substituted with one or more C5-C8 cycloalkyl groups, or a C5-C12 cycloalkyl, which may be optionally substituted with one or more C1-C30 alkyl groups, R′ is hydrogen or lower alkyl, R″ is a... Agent: Leydig, Voit & Mayer, Ltd.

20080167284 - Hair and/or scalp care compositions incorporating visnadin: The invention provides a hair and/or scalp care composition which is a shampoo composition, comprising an anionic cleansing surfactant in an amount of from 5 to 30 wt % and visnadin. The invention also provides a hair and/or scalp care composition which is a conditioner composition, comprising a cationic conditioning... Agent: Unilever Patent Group

20080167285 - Heterosubstituted n-thiolated beta-lactam compounds and methods of use: The invention relates to heterosubstituted N-thiolated beta-lactams, compositions comprising these compounds, methods for their production, and methods of use as antibiotics to inhibit the growth of bacteria. The antibacterial agents of the invention can be administered to a human or animal to treat or inhibit bacterial infection, such as that... Agent: Doran R. Pace Saliwanchik, Lloyd & Saliwanchik

20080167286 - Pharmaceutical compositions and their methods of use: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.... Agent: Paul D. Yasger Abbott Laboratories

20080167287 - Imidazotriazines and imidazopyrimidines as kinase inhibitors: The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.... Agent: Fish & Richardson PC

20080167288 - Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and... Agent: Fish & Richardson PC

20080167289 - Dihydrodiazepines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20080167290 - Combination of a serotonin reuptake inhibitor and amoxapine: The present invention relates to the use of a combination of Amoxapine and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.... Agent: Darby & Darby P.C.

20080167291 - Neurogenesis by modulating angiotensin: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.... Agent: Townsend And Townsend And Crew, LLP

20080167292 - Compounds for inhibiting mitotic progression: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.... Agent: Millennium Pharmaceuticals, Inc.

20080167293 - Pyrrolobenzodiazepines: Compounds of the formula: (I) or solvate thereof, wherein: R2 is an optionally substituted C5-20 aryl group; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, nitro, Me3Sn and halo; where R and R′ are independently selected from optionally substituted C1-12 alkyl, C3-20... Agent: Michael Best & Friedrich LLP

20080167294 - Pyrazoline compounds: m

20080167295 - Quinolinone-carboxamide compounds: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.... Agent: Theravance, Inc.

20080167296 - 1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-infective agents: e

20080167298 - Medicaments for the treatment of chronic obstructive pulmonary disease:

20080167297 - Pyrimidine derivatives for use as anticancer agents: A compound of formula (I), wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.... Agent: Astrazeneca R&d Boston

20080167299 - Thioamide derivatives as progesterone receptor modulators: Thioamide compounds, and specifically, thioamide pyrrole compounds, and preparation thereof are provided. These thioamide compounds can be used as progesterone receptor modulators, in contraception, and in the treatment of progesterone-related maladies.... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080167300 - Pyridine compounds: i

20080167301 - Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors:

20080167302 - Peptide deformylase inhibitors: Novel PDF inhibitors and novel methods for their use are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080167303 - Aryl sulfamide derivatives and methods of their use: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic... Agent: Wyeth Patent Law Group

20080167304 - Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors:

20080167305 - Quinazolines useful as modulators of voltage gated ion channels: The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Michael C. Badia Vertex Pharmaceuticals Incorporated

20080167306 - Novel heteroaryl derivative: wherein the ring Z is an optionally substituted heteroaryl, W4 is a single bond, lower alkylene, etc., Ar2 is an optionally substituted aryl, etc., W3 is a single bond, lower alkylene, etc., Ar1 is an optionally substituted arylene, etc., each of W1 and W2 is an optionally substituted lower alkylene,... Agent: Birch Stewart Kolasch & Birch

20080167307 - Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof: According to the present invention, a compound represented by the following formula (I) having a superior PPARα agonist action and concurrently showing a hypolipidemic action can be provided, and further, a compound useful as a synthetic intermediate for the compound can be provided.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080167308 - Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors: Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions... Agent: Wilson Sonsini Goodrich & Rosati

20080167310 - Modulators of peroxisome proliferator activated receptors (ppar): The present invention is directed to a compound of formula I, and pharmaceutically acceptable salts, solvates, hydrates or stereoisomer thereof, which are useful in treating Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X as well as cardiovascular diseases.... Agent: Eli Lilly & Company

20080167309 - Pharmaceutical compounds: e

20080167311 - Prostaglandin prodrugs: Novel compounds, and therapeutic methods, compositions and medicament related thereto are disclosed herein.... Agent: Allergan, Inc.

20080167312 - Preparation and utility of substituted allylamines: Disclosed herein are substituted allylamines having structural Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and the methods of their use thereof.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080167313 - 1,2,4-triazine derivatives, preparation and use thereof in human therapy: The invention concerns 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives of general formula (I), wherein: R1 and R2, identical or different, represent a branched or linear C1-C7 alkyl or alkenyl radical, a C1-C6 alkyl radical substituted by groups such as trifluoromethyl, C5-C6 cycloalkyl, nitrile, C1-C4 alkoxycarbonylvinyl, hydroxycarbonylvinyl, C1-C4 alkoxycarbonyl, carboxylate, benzyloxy or phenyl (for which... Agent: Birch Stewart Kolasch & Birch

20080167314 - Condensed imidazole compound and use thereof: wherein X1, X2 and X3 are each an optionally substituted CH or a nitrogen atom, and any one of X1, X2 and X3 is a nitrogen atom, X4 is an optionally substituted CH, R1 is an optionally substituted phenyl group or an optionally substituted heterocyclic group, and R2 is an... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080167315 - Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain: e

20080167316 - 6-heteroaryl-1,2,3,4,4a, 10b-hexahydrophenanthridines as pde4-inhibitors for the treatment of inflammatory disorders:

20080167317 - Combination therapy: This invention relates to combination therapy for the treatment of lower urinary tract symptoms (LUTS) associated with or without benign prostatic hyperplasia (BPH). The combination therapy comprises of tailored 1 adrenoceptor antagonist, which is selective for 1a over 1b subtype but non-selective for 1a over 1d subtype, in combination with... Agent: Ranbaxy Inc.

20080167318 - Pharmaceutically active pyrrolidine derivatives: i

20080167319 - 7-(4-(4-[3-chloro-2-(trifluoromethyl)phenyl]piperazin-1-yl)butoxy)-[1,8]-naphthyridin-2(1h)-one:

20080167320 - Novel arylpiperazine derivatives:

20080167321 - Pyridine derivatives for inhibiting human stearoyl-coa-desaturase: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, W, V, R2, R3, R4, R5, R5a, R6, R6a, R7,... Agent: Seed Intellectual Property Law Group PLLC

20080167322 - Substituted pyrazoles as modulators of chemokine receptors: Substituted pyrazole compounds such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis;... Agent: Merck And Co., Inc

20080167323 - Substituted triazole derivatives as oxytocin antagonists: The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).... Agent: Pfizer Inc.

20080167324 - Thiazolymethyl and oxazolylmethyl heteroaryl derivatives: are provided, as are methods for their preparation. The variables in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders... Agent: Neurogen Corporation

20080167325 - Valacyclovir compositions: Solid pharmaceutical compositions of valacyclovir or pharmaceutically acceptable salts thereof. Embodiments of the invention relate to processes for preparing solid pharmaceutical compositions, avoiding a wet granulation step.... Agent: Dr. Reddy's Laboratories, Inc.

20080167326 - Method for assessing the predisposition and/or susceptibility to copd by analysing fgf-bp1: The present invention relates to the discovery of an association between the gene encoding FGF-BP1 (fibroblast growth factor-binding protein) and chronic obstructive pulmonary disease (COPD). The invention identifies a role for FGF-BP1 in COPD. The present invention therefore relates to diagnostic techniques for the detection of COPD by detecting all... Agent: Fish & Richardson P.C.

20080167329 - Quinazolinone t-type calcium channel antagonists: The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck And Co., Inc

20080167327 - Hydrates of erlotinib hydrochloride: Erlotinib hydrochloride hydrate is formed from an aqueous solution and is useful as a pharmaceutical and as a purification intermediate.... Agent: SynthonIPInc

20080167328 - Quinazoline derivatives: l

20080167330 - Carbamoylsulphoximides as protein kinase inhibitors: The invention relates to carbamoylsulphoximides as protein kinase inhibitors of the general formula 1.... Agent: Millen, White, Zelano & Branigan, P.C.

20080167331 - Novel sulfonamides: e

20080167333 - New solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((s)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone:

20080167332 - Novel compounds 243: wherein R1, R3, R4, R5, R6, R7, and R10 are as defined in the specification, are described. The present invention also relates to pharmaceutical composition comprising said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds... Agent: Fish & Richardson P.C.

20080167334 - Compounds for binding to eralpha/beta and gpr30, methods of treating disease states and conditions mediated through these receptors and identification thereof: The current invention is in the field of molecular biology/pharmacology and provides compounds which modulate the effects of GPR30 as well as the classical estrogen receptors alpha and beta (ERα and ERβ). These compounds may function as agonists and/or antagonists of one or more of the disclosed estrogen receptors. Diseases... Agent: Coleman Sudol Sapone, P.C.

20080167335 - One pot synthesis of tetrazole derivatives of sirolimus: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale is presented, which improves currently available synthesis schemes. In one embodiment, dried rapamycin is dissolved in isopropylacetate (IPAc). The solution is cooled, and 2,6-Lutidine is added, followed slowly adding triflic anhydride at −30° C. Salts are... Agent: Squire, Sanders & Dempsey LLP

20080167336 - Azaadamantane derivatives and methods of use: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.... Agent: Paul D. Yasger Abbott Laboratories

20080167337 - Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto: e

20080167338 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Foley & Lardner LLP

20080167339 - Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors: wherein the substituents are as defined herein. The compounds of formula I wherein R2 is hydrogen are distinguished by favorable effects on disorders of lipid metabolism. They beneficially influence the HDL to LDL ratio and increase in particular the HDL level and are suitable for the prevention and treatment of... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080167340 - 6-aminoisoquinoline compounds: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and... Agent: Michael Best & Friedrich LLP

20080167341 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4... Agent: Morrison & Foerster LLP

20080167342 - Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals: in which A, Het, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080167343 - Methods and compositions using cholinesterase inhibitors: The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic... Agent: Venable LLP

20080167345 - Amide substituted indazoles as poly(adp-ribose)polymerase(parp) inhibitors: and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin... Agent: Merck And Co., Inc

20080167344 - Indoles: d

20080167346 - Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor xa inhibitors:

20080167347 - Ctgf expression inhibitor:

20080167348 - Novel sulfonamide derivatives:

20080167349 - Pharmaceutical product for injection: The present invention is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container... Agent: Nath & Associates PLLC

20080167350 - Substituted isoxazoles as fungicides: e

20080167351 - Compounds which potentiate glutamate receptor and uses thereof in medicine:

20080167352 - Sphingosine kinase inhibitors: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080167353 - Novel antiviral helioxanthin analogs: The present invention relates to novel antiviral helioxanthin analogs. These compounds may particularly be used alone or in combination with other drugs for the treatment of the following: hepadnaviruses, flaviviruses, herpesviruses and human immunodeficiency virus. In addition, compounds according to the present invention can be used to prevent or reduce... Agent: Coleman Sudol Sapone, P.C.

20080167354 - Arylycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals: e

20080167355 - Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors: The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080167356 - Farnesoid x receptor agonists: The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080167357 - Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors: e

20080167358 - Methods for obtaining a fast dissolving imidapril powder: A method for preparing a fast dissolving Imidapril powder including spraying a solution of Imidapril on at least one excipient in a granulator.... Agent: Ip Group Of Dla Piper US LLP

20080167359 - N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them: This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080167361 - Arylsulfonyl pyrrolidines as 5-ht6 inhibitors: i

20080167362 - Celecoxib compositions: Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising particulate celecoxib in an amount of about 10 mg to about 1000 mg in intimate mixture with one or more pharmaceutically acceptable excipients. The compositions are useful in treatment or prophylaxis of cyclooxygenase-2 mediated conditions and... Agent: Pharmacia Corporation Global Patent Department

20080167360 - Cycloalkylidene compounds as selective estrogen receptor modulators: The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080167363 - Modulation of neurogenesis by melatoninergic agents: The present disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of melatonin or other melatoninergic agent, optionally in combination with one or more other neurogenic agents, to stimulate or... Agent: Townsend And Townsend And Crew, LLP

20080167365 - Enhanced drug delivery in transdermal systems: A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a drug that includes a parent drug and a prodrug; and a pharmaceutically acceptable carrier, wherein the parent drug and prodrug are individually present in an amount sufficient for a pharmacological effect. In a preferred... Agent: Foley And Lardner LLP Suite 500

20080167364 - Ramipril-amine salts: The present invention relates to ramipril-amine salts, such as, primary, secondary, tertiary and quaternary salts of ramipril.... Agent: Wilson Sonsini Goodrich & Rosati

20080167366 - Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug: The present invention relates to pharmaceutical compositions containing 2-oxo-1-pyrrolidine derivatives and methods for treating Parkinson's Disease in a chronic dopamine replacement therapy using L-DOPA by administering the derivatives.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080167367 - Stable hydrate of a muscarinic receptor antagonist: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage,... Agent: Novartis Corporate Intellectual Property

20080167368 - Substituted pyrroles, compositions containing same, method for making same and use thereof: s

20080167370 - Multidrug multiligand conjugates for targeted drug delivery: Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery... Agent: Bradley Arant Rose & White, LLP Intellectual Property Department-nwj

20080167369 - Semisynthesis process for the preparation of 10-deacytyl-n-debenzoyl-paclitaxel: The invention relates to a process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel, a synthon useful for the preparation of taxanes with antitumour activity, and intermediates for the preparation thereof. The invention also discloses a process for the preparation of Docetaxel starting from said compound of formula (I).... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20080167371 - Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof: e

20080167372 - Schisandrin b preparation: The present invention provides a composition (e.g., a pharmaceutical composition) for reducing aging-related mitochondrial antioxidant status changes in a subject, wherein the composition comprises Schisandrin B. The present invention further provides a composition (e.g., a pharmaceutical composition) for reducing ischemia-reperfusion injury in an aging subject, wherein the composition comprises Schisandrin... Agent: Troutman Sanders LLP

20080167373 - Production of furanones: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, caboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives,... Agent: Morgan Lewis & Bockius LLP

20080167374 - Pesticide composition and method of use: The invention provides pesticide compositions and methods of use. In particular, pesticide compositions comprises a photolabile pesticide and a UV absorbent.... Agent: Faegre & Benson LLP Patent Docketing

20080167375 - Treatment of cutaneous neurogenic inflammation: The glyceryl fatty acid monoester of octanoic acid, i.e. 1-glyceryl monocaprylate has, unlike other glyceryl fatty acid esters, such as 1-glyceryl monocaprate, been shown to inhibit cutaneous neurogenic inflammation. Therefore, this invention features uses and dermatological compositions of 1-glyceryl monocaprylate or analogues thereof for the treatment of cutaneous neurogenic inflammation,... Agent: Foley And Lardner LLP Suite 500

20080167376 - Methods and products which utilize n-acyl-l-aspartic acid: The invention provides therapeutic methods and products for the treatment of inflammation, inflammatory diseases and conditions, and proliferative diseases and conditions. The invention also provides methods and products for inhibiting inflammation in excised cells, tissues and organs. The invention further provides oral care methods and products for the treatment of... Agent: Sheridan Ross PC

20080167377 - Novel compounds: e

20080167378 - Receptor function regulation agent: An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080167379 - Ointment: and an oleaginous base, is an ointment containing a compound which is effective for atopic symptoms, and is an ointment having low skin irritancy and excellent storage stability, thus, can be used as a pharmaceutical product effective for the pruritus caused by atopy or the like.... Agent: Sughrue Mion, PLLC

20080167380 - Acyl hydrazines as kinase inhibitors, in particular for sgk: Novel acyl hydrazides of the formula (I), in which R1-R9 have the meanings indicated in claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, generally in... Agent: Millen, White, Zelano & Branigan, P.C.

20080167381 - 5-amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonamides: Compounds of the general formula (I) in which R is heterocyclyl which is bonded via a carbon atom and is mono- or polysubstituted by C1-6-alkyl, trifluoromethyl, nitro, amino, C1-6-alkylamino, di-C1-6-alkylamino, C2-6-alkenyl, C2-6-alkynyl, C1-6-alkoxy, C1-6-alkylcarbonyloxy, C0-6-alkylcarbonylamino, C1-6-alkoxycarbonylamino, hydroxyl, halogen, oxide, cyano, optionally N-mono- or N,N-di-C1-8-alkylated carbamoyl, optionally esterified carboxyl or C1-6-alkylenedioxy,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20080167382 - Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation... Agent: Quarles & Brady LLP

20080167383 - Biostatic polymer formed articles: Compositions comprising a polyvinyl alcohol in combination with a biocide which is a plasticiser, such as a quaternary ammonium compound, or in combination with a biocide and a compatible plasticiser, and wherein the biocide forms a complex with the polyvinyl alcohol, said combination having been heated to above its melting... Agent: Wolf Greenfield & Sacks, P.C.

20080167384 - Use of zeaxanthin for the treatment of diseases of the peripheral retina: Zeaxanthin is useful for the treatment or prevention of diseases of the peripheral retina, and/or for improvement of peripheral vision.... Agent: Nixon & Vanderhye, PC

20080167385 - Crystal structure of human proliferating cell nuclear antigen (pcna) and uses thereof: The present invention relates to crystals comprising human PCNA, and methods and assays for designing and identifying small molecule PCNA inhibitors using said crystals.... Agent: Lahive & Cockfield, LLP

20080167386 - Disheveled pdz modulators: The invention provides modulators of Dvl PDZ-ligand interaction, and methods of identifying and using these modulators.... Agent: Genentech, Inc.

20080167387 - Microglia facilitated amyloidogenesis assay: The present invention describes methods to identify compounds that prevents or treat amyloid accumulation in the brain, as mediated by microglia or cells of macrophage lineage. The present invention further describes compositions containing such compounds, methods of preparing such compositions and methods of using such compositions. The compositions are useful... Agent: Pfizer Inc Steve T. Zelson

20080167388 - Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis: A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline... Agent: Omeros Medical Systems, Inc.

  
07/03/2008 > patent applications in patent subcategories. cataloged by category listing

20080161226 - Activatable clostridial toxins: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.... Agent: Allergan, Inc.

20080161225 - Antifungal protein and usage thereof: The present invention relates to an antifungal protein gene and cDNA sequence thereof, which is obtained by mining the whole genome sequences of Monascus pilosus BCRC 38072 and the unigene database. The gene can encode an antifungal protein MAFP1. A purified protein obtained from M. pilosus culture broth having molecular... Agent: Ladas & Parry LLP

20080161227 - Blood pressure lowering peptides from glycomacropeptide: A process to produce IPP from a protein source whereby the protein source comprises a protein having the -I-P-P- sequence and having in the protein amino acid sequence at least 6 times more -I-P-P- present than -V-P-P- (molar basis) which comprises hydrolysing the protein source to liberate at least 40%... Agent: Nixon & Vanderhye, Pc

20080161229 - Compounding ingredients for basic cosmetics and basic cosmetics: The present invention relates to a compounding ingredients for basic cosmetics and basic cosmetics containing the compounding ingredients which contain enzymes or hydrolysis products of nucleoprotein and/or DNA or RNA, or deoxy oligonucleotide, deoxy mononucleotide, oligopeptide, oligonucleotide mononucleotide separated from the hydrolysis products, or at least two kinds of mixtures... Agent: Oliff & Berridge, Plc

20080161228 - Methods of identifying biochemical pathways: Methods for metabolomically determining the biological affects of compounds are described.... Agent: Lahive & Cockfield, LLP

20080161230 - Methods and kits for stabilising, protecting and solubilising proteins: The invention relates to methods and kits for stablilising or solubilising a protein, characterised by contacting the protein with a sugar polymer derivative, said sugar polymer derivative not being an α-, β- or γ-cyclodextrin. Inulin derivatives and glucoside derivatives are suitable sugar polymer derivatives for use in methods and kits... Agent: Wolf Greenfield & Sacks, P.c.

20080161231 - Methods and compositions for promoting organ development: Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or foetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof,... Agent: Jones Day

20080161232 - C5a receptor antagonist: The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure: (I), whereby X1 is a radical having a mass of about 1-300, whereby X1 is preferably selected from the group comprising R5-, R5-CO—, R5-N(R6)-CO—, R5-O—CO—, R5-SO2—, R5-N(R6)-SO2—, R5-N(R6)-, R5-N(R6)-CS—, R5-N(R6)-C(NH)—, R5-CS—, R5-P(O)OH-5 R5-B(OH)—,... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080161233 - Sustained release formulation of a peptide: or a pharmaceutically acceptable salt thereof, and a copolymer comprising poly-(I)-lactic-glycolic-tartaric acid (P(I)LGT), wherein the amino group of said Compound (A) is ionically bound to a carboxyl group of the P(I)LGT. The present invention further pertains to a process for making said sustained release complex. Further still, the present invention... Agent: Biomeasure, Incorporated

20080161239 - Agent for prevention/treatment of neurodegenerative disease: A compound that promotes the ubiquitination of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or a partial peptide thereof or a salt thereof, or a salt thereof, a... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080161243 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080161244 - Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes: The present invention provides peptides which stimulate the release of insulin. The peptides, based on GIP 1-42 include substitutions and/or modifications which enhance and influence secretion and/or have enhanced resistance to degradation. The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick & Lockhart Nicholson Graham)

20080161234 - Composition comprising lactic acid and lactoferrin: A composition comprising lactic acid and lactoferrin and/or a peptide fragment thereof, for the treatment and/or prophylaxis of conditions in the urogenital tract, is disclosed. Also disclosed is the use of such a composition for the preparation of a medicament for the treatment and/or prophylaxis of conditions in the urogenital... Agent: Harness, Dickey & Pierce, P.L.C

20080161235 - Corticotropin releasing factor receptor-2 inhibitors and uses thereof: In some aspects, the invention relates to methods for increasing insulin-sensitivity and/or decreasing insulin secretion in an individual by reducing or inhibiting corticotropin releasing factor 2 (CRFR2) signaling. CRFR2 antagonists may block agonism by one or more CRFR2 agonist, for example Ucn 2 or Ucn 3. Methods according to the... Agent: Fulbright & Jaworski, L.l.p.

20080161240 - Cystine-knot polypeptides: cloaked-2 molecules and uses thereof: The present invention relates to novel Cloaked-2 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing Cloaked-2 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with Cloaked-2 polypeptides.... Agent: Marshall, Gerstein & Borun LLP

20080161237 - Formulation for a viptadil: The present invention relates to pharmaceutical formulations of Aviptadil and its derivatives. The stability of the Aviptadil formulation was shown to be improved by a formulation having a defined concentration of Aviptadil prepared in a buffer having a defined pH range.... Agent: J C Patents, Inc.

20080161242 - High pressure treatment of proteins for reduced immunogenicity: Protein compositions with reduced immunogenicity are disclosed, as well as methods for producing such compositions.... Agent: Morrison & Foerster LLP

20080161241 - Inhibitor of cardiac tachyarrhythmias: Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and/or decreasing the incidence and/or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK)... Agent: Dunlap Codding & Rogers, P.c.

20080161238 - Nucleic acid molecules encoding bacterial autoinducer inactivation proteins as targets for engineering disease resistance: Disclosed are an isolated nucleic acid molecule encoding a bacterial autoinducer inactivation protein, the encoded protein, and anti-bacterial uses therefor.... Agent: Rothwell, Figg, Ernst & Manbeck, P.c.

20080161236 - Therapeutic nucleic acid-3'-conjugates: Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional... Agent: Winstead Pc

20080161245 - Protein-binding anthracycline peptide derivatives and drugs containing them: The invention pertains to low-molecular anthracycline-peptide derivatives with PSA-cleavable peptide sequences, which contain a protein-binding group.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080161246 - Cytochrome p450 oxidase inhibitors and uses thereof: e

20080161247 - Synergistic composition for modulating activity of substrate analogs for nad+, nadp+, nadh or nadph dependent enzymes and process thereof: The present disclosure provides a composition for enhancing effect of an inhibitor in inhibiting NAD+/NADP+ or NADH/NADPH dependent enzymes. The inhibition of the NAD+/NADP+ or NADH/NADPH dependent enzymes such as Enoyl-ACP reductase (ENR) by the composition of the present disclosure serves as a target for treating malaria and other infectious... Agent: Ladas & Parry LLP

20080161248 - Methods and compositions for therapeutic treatment: Methods and compositions are described for the modulation of central nervous system and/or fetal effects of calcineurin inhibitors. Methods and compositions are described for the modulation of efflux transporter activity to increase the efflux of calcineurin inhibitors out of a physiological compartment and into an external environment. In particular, the... Agent: Wilson Sonsini Goodrich & Rosati

20080161250 - Topical treatment or prevention of ocular infections: The topical application of an azalide antibiotic such as azithromycin to the eye is useful in treating or preventing ocular infections. In one embodiment, the azalide antibiotic is supplied to the eye in a depot for sustained release. A more convenient dosing regimen can also be provided by the use... Agent: Richard Aron Osman

20080161249 - Use of novel antibacterial compounds: The present invention relates to the use of novel antibacterial compounds, and pharmaceutical compositions containing these compounds.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080161252 - Composition and methods for the treatment of proliferative diseases: e

20080161253 - Composition for the treatment of nasopharyngeal carcinoma and method of use thereof: Disclosed is a novel drug combination which is useful for the treatment of nasopharyngeal carcinoma, said novel drug combination comprising one or more of a farnesyl transferase inhibitor and one or more of an anthracycline.... Agent: Alan F. Feeney, Esq.

20080161251 - Pharmaceutical compounds: The invention provides a combination of a cytotoxic compound or signalling inhibitor and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NRg(C═O)... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080161254 - Hcv inhibitors: The present invention is directed to compounds that are antiviral agents. Specifically, the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Townsend And Townsend And Crew, LLP

20080161262 - Compositions and methods for the systemic treatment of arthritis: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.... Agent: Chalker Flores, LLP

20080161261 - Defective sindbis viral vectors: Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for... Agent: Darby & Darby P.c.

20080161263 - Fusion proteins of mycobacterium tuberculosis: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and nucleic acids encoding such compositions and fusion proteins. The compositions of the invention increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and... Agent: Townsend And Townsend And Crew, LLP

20080161258 - Hsp and supraventricular arrhythmia: The invention relates to the field of biology, molecular biology and medicine More specifically, the invention relates to a method for at least in part preventing or delaying or decreasing damage to a cardiac cell induced by a supraventricular arrhythmia. The invention provides a method for preventing, delaying or decreasing... Agent: Trask Britt

20080161259 - Inhibitory pellion nucleic acids: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.... Agent: Immunex Corporation Law Department

20080161260 - Methods for detecting and quantifying cell proliferation in vivo: The invention provides a rapid, sensitive method for detecting and quantifying in vivo cell proliferation in a mammal.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20080161257 - Oligonucleotide-containing pharmacological compositions and their use: The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.... Agent: Patent Docket Administrator Lowenstein Sandler Pc

20080161256 - Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating gene expression using short interfering nucleic acid (siNA) molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA... Agent: Mcdonnell, Boehnen, Hulbert And Berghoff, LLP

20080161255 - Use of parp inhibitors for prevention and treatment of diabetic and insulin resistance complications: The present invention provides methods of inhibiting the development or progression of atherosclerotic, microvascular, or neurologic disease due to diabetes or insulin resistance in a mammal, or conditions resulting therefrom. The methods involve specifically inhibitingpoly(ADP-ribose) polymerase (PARP) activity or accumulation in the mammal. Also provided are antibodies that specifically react... Agent: Amster, Rothstein & Ebenstein LLP

20080161264 - Triazolyl tropane derivatives: This invention relates to novel triazolyl tropane derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by blocking or reducing the binding... Agent: Edwards Angell Palmer & Dodge LLP

20080161265 - Use of lactulose in the treatment of autism: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are... Agent: Kristina M. Grasso

20080161266 - Ophthalmic alginate composition related methods of manufacture and methods of use: The present invention is directed to an ophthalmic composition comprising alginate having a minimum of about 0% and a maximum of about 50% guluronic units bound to an adjacent guluronic unit as a percentage of the total number of monomeric units in the alginate. The composition further includes a cationic... Agent: Bausch & Lomb Incorporated

20080161267 - Mitoquinone derivatives used as mitochondrially targeted antioxidants: This invention relates to pharmaceutically acceptable amphiphilic antioxidant compounds, compositions and dosage forms comprising said compounds, and methods and uses reliant on said compounds. The exemplified compounds are all mitoquinone derivatives, being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives. The compounds, compositions, dosage forms, uses and methods are... Agent: Seed Intellectual Property Law Group Pllc

20080161270 - Angiogenesis inhibitors: i

20080161269 - Compounds 620:

20080161268 - Quaternary ammonium salt antibacterial and water-borne coating material having antibiotic property containing the same: in which M represents, for example, Si; R represents a single bond or a C1-C4 alkyl group; R1-R3 are the same or different to each other and represent a C3-C18 alkyl group, respectively; R4 represents a C1-C8 alkyl group or hydrogen; R5-R6, are the same or different to each other... Agent: Jianq Chyun Intellectual Property Office

20080161271 - Bicyclic carbamoylpyridone derivative having hiv integrase inhibitory activity:

20080161272 - Ceramide derivatives, method for preparing the same, and therapeutic agent for treating atopic dermatitis comprising the ceramide derivatives: wherein, R1 and R2 are each independently straight or branched alkyl groups having 4 to 22 carbon atoms. The therapeutic agent for treating atopic dermatitis including the ceramide derivatives as active ingredients according to the present invention may be useful to treat atopic dermatitis, or treat other skin diseases that... Agent: Thomas M. Galgano

20080161273 - Method of using adapalene in acne maintenance therapy: The present invention provides a method of administering adapalene for the maintenance therapy of acne vulgaris to prevent acne recurrence or reduce the severity of the acne recurrence.... Agent: Buchanan, Ingersoll & Rooney Pc

20080161274 - Compounds and methods for inhibition of bone loss: The invention relates to methods of treating or preventing bone loss, as in osteoporosis, metastatic bone disease, or periodontitis, comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound.... Agent: Ropes & Gray LLP

20080161275 - Compositions and methods for the treatment of inflammatory disease: The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound.... Agent: Ropes & Gray LLP

20080161276 - Compositions forming non-lamellar dispersions: The present invention relates to compositions containing a) at least one monoacyl lipid; b) at least one diacyl glycerol and/or tochopherol; and c) at least one fragmentation agent; and optionally an active agent. The compositions are capable of self-dispersing to provide colloidal non-lamellar particles upon contact with an aqueous fluid.... Agent: Nixon & Vanderhye, Pc

20080161277 - Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol: Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as... Agent: Ostrolenk Faber Gerb & Soffen

20080161281 - Amino-substituted tricyclic derivatives and methods of use: wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by... Agent: Paul D. Yasger Abbott Laboratories

20080161280 - Inhibitors of poly(adp-ribose)polymerase: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20080161279 - Methods of treating obesity: The invention is directed to methods for treating and/or controlling obesity in a patient. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe).... Agent: Goodwin Procter LLP Patent Administrator

20080161282 - Cytotoxic agents and methods of use: Disclosed are compounds that inhibit proteasomic activity in cells. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly cell proliferative conditions, such as cancer and inflammatory conditions.... Agent: King & Spalding LLP

20080161278 - 2-azetidinyl-4-(1h-pyrazol-3-ylamino) pyrimidines as inhibitors of insulin-like growth factor-1 receptor activity: A compound of formula (I): wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.... Agent: Astrazeneca R&d Boston

20080161286 - Beta d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it: c

20080161285 - Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20080161284 - Delta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.:

20080161283 - Ligands for g-protein coupled receptors: The invention relates to the generation of a library of compounds enriched in agonist and antagonists for members of the G-protein coupled class of receptors (GPCRs). The library contains compounds of general formula (I) wherein y is any integer from 1 to 8; z is one integer from 0 to... Agent: Schwegman, Lundberg & Woessner, P.a.

20080161287 - Bicyclic compound, production and use thereof: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent... Agent: Edwards Angell Palmer & Dodge LLP

20080161288 - Compounds: e

20080161289 - Fused thiazole derivatives having affinity for the histamine h3 receptor: The present invention relates to novel fused thiazole derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080161290 - Serine hydrolase inhibitors: Provided herein are benzoxazinone compounds of formula I and compositions containing the compounds. The compounds and compositions are useful in the methods of inhibiting the action of serine hydrolase, including neutrophil elastase. In certain embodiments, the compounds and compositions are useful in the prevention, amelioration or treatment of serine hydrolase-mediated... Agent: Jones Day

20080161291 - Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals: The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions.... Agent: Merchant & Gould Pc

20080161292 - Inhibitors of poly(adp-ribose)polymerase: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods of treating patients using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20080161293 - Antitumor agent: h

20080161294 - Urea derivative, medicinal composition containing the same, and medicinal use of these: In the formula, R1 represents a hydrogen atom or a C1-6 alkyl group which may have a substituent, R2 is a hydrogen atom or a C1-6 alkyl group, R3 is a hydrogen atom, a C1-6 alkyl group or the like, R4, R5 and R6 are independently a hydrogen atom, a... Agent: Stuart D. Frenkel Frenkel & Associates, P.c.

20080161295 - Substituted benzothiadiazinedioxide derivatives and methods of their use: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic... Agent: Wyeth Patent Law Group

20080161296 - Compositions comprising nebivolol: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular... Agent: Frost Brown Todd, Llc

20080161297 - Rho kinase inhibitors: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080161298 - Spiro-piperidine derivatives: s

20080161299 - Spiro-piperidine derivatives:

20080161301 - 2-oxy-benzoxazinone derivatives for the treatment of obesity:

20080161300 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and... Agent: Amgen Inc.

20080161302 - Antifungal agents: Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents: (I) wherein: R1, R2, R3, R4, R5, R6, R7, X and X1 are as defined herein. Certain compounds of formula (I) are also provided. Compounds of formula (T), and agriculturally acceptable... Agent: Fulbright & Jaworski, LLP

20080161303 - Imidazo- and triazolo-pyridine compounds and methods of use thereof: wherein A, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as... Agent: Amgen Inc.

20080161304 - Spiro-piperidine derivatives: e

20080161305 - C-met modulators and methods of use: The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds... Agent: Leydig Voit & Mayer, Ltd

20080161306 - Pyrrole derivatives as dna gyrase and topoisomerase inhibitors: Compounds of formula (I) and their pharmaceutically acceptable salts are described: Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20080161307 - Organic compounds: A method for the treatment of delayed gastric emptying, in a patient in need of such treatment, which comprises administering an effective amount of a 5-HT4 agonist, e.g. tegaserod or salts or hydrates thereof, to the patient.... Agent: Novartis Corporate Intellectual Property

20080161308 - Hydroxyphenol derivatives, processes for the preparation thereof, pharmaceutical compositions them, and therapeutic uses thereof: Compounds of the formula (I): in which A, R1, R2, X, Y and Z are defined in the description, the processes for the preparation of these compounds, the uses thereof for the treatment of dyslipidaemia, atherosclerosis and diabetes, and the pharmaceutical compositions comprising them.... Agent: Millen, White, Zelano & Branigan, P.c.

20080161309 - Novel compounds: wherein R1, R2, R3, and n have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of conditions including urinary disorders, pain, premature ejaculation, ADHD and fibromyalgia. Also provided are pharmaceutical compositions comprising one or more compounds of... Agent: Pharmacia Corporation Global Patent Department

20080161310 - Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity: The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.... Agent: Aventis Pharmaceuticals Inc.

20080161311 - Nitrogen-containing fused ring compound and use thereof as hiv integrase inhibitor: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080161312 - Derivatives of pyrrolo-pyrazines having a kinase inhibitory activity and their biological applications: The invention relates to pyrrolo[2,3b]-pyrazine derivatives having the general Formula (I) wherein R2 and R3 are identical or different and represent H, C1-C6 alkyl, said alkyl being a straight or branched-chain alkyl, which can be substituted, R6 is an optionally substituted aromatic cycle Ar or a cycloalkyl, said cycloalkyl being... Agent: Nixon & Vanderhye, Pc

20080161313 - Diazabicyclononene derivatives and use thereof: The invention relates to a novel 3,9-diazabicyclα[3.3.1]nonene derivative of formula (I) and the enantiomers thereof and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing at least one compound of formula (I) or (I′) and especially their... Agent: Hoxie & Associates Llc

20080161314 - Novel diazabicyclic aryl derivatives and their medical use: This invention relates to novel diazabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse... Agent: Birch Stewart Kolasch & Birch

20080161315 - Indoles: i

20080161316 - Indoles:

20080161317 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent: Merck And Co., Inc

20080161318 - Novel compositions and uses thereof: Compositions and their use in the treatment or prevention of hyperglycemia and related diseases or disorders are disclosed.... Agent: Wilmerhale/boston

20080161319 - Methods for treating inflammatory conditions: The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not... Agent: Pepper Hamilton LLP

20080161320 - Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety: The present invention relates to fused bicyclic pyrimidine containing zinc-binding moiety based derivatives that have unique properties as protein tyrosine kinase (PTK) inhibitors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, Pc

20080161321 - Use of renin inhibitors in therapy: The present is directed to a method for the prevention of, delay progression to or treatment of a condition or disease selected from diabetes type 2 (associated with or without hypertension), severe hypertension, PH, malignant hypertension, isolated systolic hypertension, familial dyslipidemic hypertension, endothelial dysfunction (with or without hypertension), survival post-MI,... Agent: Novartis Corporate Intellectual Property

20080161322 - Pyrimidine compounds and use thereof: The invention relates to pyrimidine compounds of general formula (I), and to the use of these compounds of general formula (I) and of the physiologically compatible acid addition salts of compounds (I) for producing a pharmaceutical agent for treating diseases, which respond to the influence of dopamine D3 receptor antagonists... Agent: Wood, Phillips, Katz, Clark & Mortimer

20080161323 - Piperazine derivatives of alkyl oxindoles: The present invention is concerned with new indol-2-one derivatives of Formula (I), which have favourable activity profile for the prophylaxis and treatment of disorders in the central nervous or in the cadiovascular system.... Agent: Birch Stewart Kolasch & Birch

20080161324 - Compositions and methods for treatment of viral diseases: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B,... Agent: Clark & Elbing LLP

20080161325 - 1, 3, diamino-2-hydroxypropane pro-drug derivatives: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080161326 - Novel sulfone amide amide derivatives: e

20080161327 - Substituted 9-alkyladenines and the use thereof: The invention relates to substituted 9-alkyladenines of Formula I: or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined as set forth in the specification. The invention is also directed to the use of such compounds to inhibit adenosine A1 receptor activation in a mammal. The compounds of the present... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080161329 - Pharmaceutical uses: wherein X and Y are each independently of the other N and/or CH and the ring A is unsubstituted or mono- or poly-substituted by substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl; and pharmaceutically acceptable salts thereof for treatment of chronic fatigue syndrome... Agent: Novartis Corporate Intellectual Property

20080161328 - Substituted 9-alkyladenines and the use thereof: Provided are 5-substituted quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.... Agent: Jones Day

20080161330 - Pyrimidines as igf-i inhibitors: A compound of formula (I) wherein the substituents are as defined in the text for use in inhibiting insulin-like growth factor 1 receptor activity in a warm blooded animal such as man.... Agent: Astrazeneca R&d Boston

20080161332 - Azaspiro derivatives: c

20080161333 - Azaspiro derivatives:

20080161331 - Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses: The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, (I), wherein A1 is CH C(CH3) or N; R1 is hydrogen or halogen; R2 is (II); A2 is O or S; R3 is... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080161334 - Macrolides: A mixture comprising a poly-ene macrolide and an antioxidant. Preferably, the poly-ene macrolide is rapamycin and the antioxidant is 2,6-di-tert.-butyl-4-methylphenol. The presence of the antioxidant improves the stability of the poly-ene macrolide to oxidation.... Agent: Novartis Corporate Intellectual Property

20080161335 - Oral formulations: A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed.... Agent: Ariad Pharmaceuticals, Inc. Ariad Gene Therapeutics, Inc.

20080161336 - Orally bioavailable cci-779 formulations: A CCI-779 oral dosage form is provided in which, after oral administration to a subject, the CCI-779 has a whole blood peak concentration (Cmax) of 5.4±1.8 ng/mL and an area under the curve (AUC) of about 66± about 22 ng-hr/ml and the sirolimus has a Cmax of 18.7±9.6 ng/mL and... Agent: Howson And Howson/wyeth Cathy A. Kodroff

20080161338 - Novel pyrrolodihydroisoquinolines as pde 10 inhibitors: The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of PDE10.... Agent: Nath & Associates Pllc

20080161337 - Use of rifaximin for the treatment of chronic prostatitis: Chronic prostatitis (CP) is a syndrome characterized by pelvic pain in one or more areas (perineum, lower abdominal, testicular and/or penile), urinary frequency, urinary urgency, sexual dysfunction and/or ejaculatory pain. CP type IIIa is the most common type of prostatitis and is defined by having sterile EPS and a leukocyte... Agent: Husch Blackwell Sanders LLP

20080161339 - Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors: r

20080161340 - Tetrahydroquinilinones, tetrahydronaphthyridones and derivatives thereof: Tetrahydroquinolinone and tetrahydronaphthyridone cannabinoid receptor ligand compounds and stereoisomers, mixtures of stereoisomers, prodrugs, pharmaceutically acceptable salts, hydrates, solvates, acid salt hydrates, and isomorphic crystalline forms thereof are described. The compounds conform to the structure of formula I:... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20080161341 - Novel imidazothiazoles and imidazoxazoles: t

20080161342 - Novel polymorph of mutilin: Disclosed is a novel polymorphic form of the compound of formula (I) also known as mutilin 14-(exo-8-methyl-8-azabicyclo [3.2.1]oct-3-ylsulfanyl)-acetate, a process for the preparation of the polymorphic form, pharmaceutical compositions comprising the polymorphic form, and the use of the polymorphic form in medicine, particularly in antibacterial therapy.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080161343 - Sigma 2 receptor ligands and therapeutic uses therefor: A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds... Agent: Sonnenschein Nath & Rosenthal LLP

20080161345 - Aryl sulfonamides: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.... Agent: Brinks Hofer Gilson & Lione

20080161344 - Melanin concentrating hormone receptor ligands: substituted tetrahydroisoquinoline analogues: Melanin concentrating hormone receptor ligands (especially substituted tetrahydroisoquinoline analogues), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders... Agent: Neurogen Corporation

20080161346 - Compounds and methods of use: Selected compounds are effective for prophylaxis and treatment of diseases, such as VEGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention... Agent: Amgen Inc.

20080161347 - Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use: Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20080161348 - Ptx3-gene expression inhibitor: b

20080161349 - Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof: where X and Y independently are oxygen, nitrogen or sulfur; R1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiolester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alcohol, ethers or nitriles; R2 and R3 are hydrogen or R4; R4 is methyl, benzyl carboxylic acid, benzyl... Agent: Fulbright & Jaworski, L.l.p.

20080161350 - Use of quinoline derivatives with anti-integrase effect and applications thereof: The invention relates to the use of 8-hydroxyquinoline 7-carboxylic acid derivatives in order to produce integrase inhibiting medicaments, capable of blocking viral replication in the stages preceding integration, and if appropriate, at the level of this integration stage, these medicaments being usable for the treatment of retroviral pathologies, in particular... Agent: Foley And Lardner LLP Suite 500

20080161351 - Linked biaryl compounds: Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.... Agent: Jones Day

20080161352 - Substituted benzo-condensed cycloheptanone derivatives and the use thereof for medicament production: The invention relates to substituted benzo-condensed cyclohexanone derivatives, to a method for the production thereof, to medicaments containing said derivatives and to the use of the inventive compounds for producing medicaments.... Agent: Crowell & Moring LLP Intellectual Property Group

20080161353 - 8-hydroxy quinoline derivatives: e

20080161354 - Stable s-nitrosothiols, method of synthesis and use:

20080161355 - Combinations of pyrazole kinase inhibitors and further antitumor agents: The invention provides a combination of a compound having the formula (0) and two or more further anti-cancer agents: or salts or tautomers or N-oxides or solvates thereof; wherein X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C═O, NR9(C═O)... Agent: Heslin Rothenberg Farley & Mesiti Pc

20080161356 - Devices and methods for pain management: The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a... Agent: Thomas P. Mccracken Durect Corporation

20080161357 - Devices and methods for pain management: The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a... Agent: Thomas P. Mccracken Durect Corporation

20080161359 - Crystalline form of rabeprazole sodium: Rabeprazole sodium in the monohydrate crystalline form, pharmaceutical compositions thereof, the use thereof in therapy, a process for its preparation, and the use thereof for the purification of rabeprazole sodium.... Agent: Griffin & Szipl, Pc

20080161358 - Cyanoamide compounds useful as malonyl-coa decarboxylase inhibitors: The present invention provides previous methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management... Agent: Fish & Richardson Pc

20080161360 - Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active... Agent: Jones Day

20080161361 - Use of pyridone derivatives in the prevention or treatment of tissue or organ toxicity induced by cytotoxic agents and radiation: The present invention is directed to a novel use of pyridone derivatives such as pirfenidone for the prevention and treatment of damages to tissues or organs induced by various cytotoxic agents, such as chemotherapeutic agents, biologics, immunosuppressants and radiation. Such prophylactic and/or therapeutic effects of the pyridone derivatives make it... Agent: Wilson Sonsini Goodrich & Rosati

20080161362 - Metalloprotein inhibitors: The present invention relates to metalloprotein inhibitors comprising: a. an organic substituent and at least one zinc binding group (ZBG) covalently attached thereto; or b. a ZBG substituted by a side chain wherein the ZBG is of formula (I): wherein X is O or S and each R1, R2, R3,... Agent: Schwegman, Lundberg & Woessner, P.a.

20080161363 - 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to 2-aminopyridine compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of... Agent: Merck And Co., Inc

20080161364 - Enteric medicinal composition for oral use: An object of the present invention is to provide a composition having both of enteric property and dosing property that a conventional composition has not had. The present invention, which can achieve the above object, relates to an enteric medicinal composition, comprising a drug ingredient, pectin, alginic acid or derivative... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080161365 - Methylene derivatives: This invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition; a method of treating a disease mediated by an MMP-13 enzyme in a mammal; and a therapeutic combination containing at least two pharmaceutically active components, wherein R1, Q, W1, W2, W2a, R3a,... Agent: Pfizer Inc.

20080161366 - Aminoalkyl substituted aryl sulfamide derivatives and methods of their use: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic... Agent: Wyeth Patent Law Group

20080161369 - Epothilone derivative for the treatment of hepatoma and other cancer diseases: The present invention relates to a method of treating a warm-blooded animal, especially a human, having a cancer disease selected from hepatoma; primary fallopian tube cancer; primary peritoneal cancer; breast cancer progressing after treatment with hormonal agents or radiotherapy; renal cell carcinoma progressing after treatment with a cytokine, radiotherapy and/or... Agent: Novartis Corporate Intellectual Property

20080161367 - Insecticidal mixtures: The present invention relates to plant-protecting active ingredient mixtures comprising fipronil and clothianidin having synergistically enhanced insecticical action by applying said mixtures to the plants or to the locus thereof and to a method for the protection of seeds comprising contacting the seeds before sowing and/or after pregermination with the... Agent: Hutchison Law Group Pllc

20080161368 - Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome: e

20080161370 - Benzothiazol-2-one derivatives as lipase and phospholipase inhibitors: The invention relates to benzothiazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20080161371 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20080161373 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa,... Agent: Louis J. Wille Bristol-myers Squibb Company

20080161372 - Methods for the treatment of hypertension: This invention relates to the treatment of hypertension, cardiac dysfunction or stroke by the administration of an estrogen receptor beta (ER&bgr;) selective agonist either as a single agent, or in combination with other agents.... Agent: Merck And Co., Inc

20080161374 - Pyrazole compounds and uses related thereto: Substituted pyrazoles are provided that are useful for the treatment of, for example, diabetes, obesity and metabolic syndrome.... Agent: Foley And Lardner LLP Suite 500

20080161375 - Solubilizing of metronidazole: Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea.... Agent: Buchanan, Ingersoll & Rooney Pc

20080161376 - Method of treating candida isolates: The present invention relates to methods of treatment of vulvovaginitis caused by nonspecified Candida isolates using controlled release antimycotic delivery systems. The invention utilizes a minimal number of administrations to obtain cessation of the condition. The methods and systems are especially effective against any Candida species causing vaginal irritation, and... Agent: Kv Pharmaceutical Company

20080161377 - Use of l-2-thiohistidine or one of its derivatives as a depigmenting agent in cosmetics: The invention relates to the use of L-2-thiohistidine, or a cosmetically acceptable salt or ester of its acid group, as a depigmenting agent in a cosmetic composition or for the preparation of a cosmetic composition. It further relates to a method of cosmetic care for toning down or eliminating pigment... Agent: Merchant & Gould Pc

20080161378 - Novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als: There is provided a medicament for treating amyotrophic lateral sclerosis (ALS) or symptoms caused by ALS and/or suppressing the progression thereof, which is characterized in the usage, dosage and administration period of the pyrazolone derivative represented by the following formula (wherein each symbol indicates the same meaning as that defined... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080161379 - Methods of treating diabetes mellitus: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080161380 - Amino acid composition: The present invention herein provides an amino acid composition which consists essentially of (1) glycine, (2) at least one member selected from the group consisting of proline and alanine, and (3) at least one member selected from the group consisting of glutamine and glutamic acid; as well as such an... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080161381 - Compositions comprising an no donor and a dithiolane and their use for improvement of sexual function: The present invention relates to solid compositions comprising a substance which improves nitric oxide (NO) availability, re. an NO donor or a precursor of the biosynthesis of nitric oxide or an direct or indirect NO agonist, with arginine being a preferred compound, in combination with a dithiolane, with α-lipoic acid... Agent: Darby & Darby P.c.

20080161382 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20080161384 - Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound: A method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by an insect or arthropod sting or bite, or a skin contact with a noxious weed or plant is disclosed. The method includes topically applying a dermatological composition containing an avermectin compound to an affected area immediately after said sting... Agent: Melvin K. Silverman And Assocs Pc

20080161385 - Composition inhibiting sex hormone-binding globulin: By finding out a novel use of isoflavones originating in natural materials and being highly safe even when added to foods, it is intended to provide a composition useful in improving various symptoms with the use thereof. It is unexpectedly found out that isoflavones contained in a large amount in... Agent: Wenderoth, Lind & Ponack, L.l.p.

20080161386 - Methods and compositions for improving cognitive function: This invention relates to compositions, and methods of use thereof, for (i) enhancing executive cognitive function(s) (for example, decision making, planning, working memory, multitasking, judgment, numerical problem-solving, reading comprehension), and/or (ii) increasing blood flow in brain vasculature, comprising administering to a subject in need thereof, certain polyphenols such as flavanols,... Agent: Nada Jain, P.c.

20080161387 - Salts, addition compounds and complex compounds of guinadinoacetic acid: The present invention provides new salts and/or addition compounds and/or complex compounds of guanidinoacetic acid with malic acid, aspartic acid, ascorbic acid, succinic acid, pyruvic acid, fumaric acid, gluconic acid, α-ketoglutaric acid, oxalic acid, pyroglutamic acid, 3-nicotinic acid, lactic acid, citric acid, maleic acid, sulfuric acid, acetic acid, formic acid,... Agent: Fulbright & Jaworski, LLP

20080161388 - Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base: The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzo-furancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a... Agent: Darby & Darby P.c.

20080161389 - Method of treating ocular hypertension and intestinal disorders by using dianhydrohexite mononitrate derivatives: The present invention relates to a method of treating an ophthalmological disease mediated by ocular hypertension or an intestinal disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a tautomer, a pharmaceutically acceptable salt, a prodrug or a solvate... Agent: Moore & Van Allen Pllc

20080161390 - Ester compound and its use: (5-Benzl-3-furyl)methyl 2,2-dimethyl-3-((E)-2-cayano-3-methoxy-3-oxo-1-propenyl)cyclopropanecarboxylate has an excellent pesticidal activity, and a pesticidal composition comprising it as an active ingredient is useful for controlling pests.... Agent: Panitch Schwarze Belisario & Nadel LLP

20080161391 - Novel curcumin analogues and uses thereof: The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to... Agent: Myers Bigel Sibley & Sajovec

20080161392 - Liquid concentrate for the preservation of cosmetic and pharmaceutical products: The invention relates to a liquid concentrate for the preservation of cosmetic an pharmaceutical prod nets which comprises 3-iodo-2-propynyl butylcarbamate (IPBC), at least on liquid carrier selected from the group consisting of: polyvalent alcohols, glycol esters and glycol ethers, and at least one stabilizer selected from the group consisting of:... Agent: Young & Thompson

20080161393 - Use of prodrugs of gaba analogs for treating disease: Methods of using prodrugs of GABA analogs and pharmaceutical compositions thereof to treat migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel syndrome, social phobia, Parkinson's disease, asthma, cough, or chronic obstructive pulmonary disease, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating migraine, fibromyalgia, amyotrophic lateral sclerosis, irritable bowel... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080161394 - Cosmetic composition comprising at least one volatile carbonic acid ester: t

20080161395 - Derivatives of aminobutanoic acid inhibiting cpt: The invention relates to a new class of compounds with action inhibiting carnitine palmitoyl transferase (CPT), pharmaceutical compounds which contain at least one new compound according to the invention, and their therapeutic use in the treatment of hyperglycaemic conditions such as diabetes and the pathologies associated with it, congestive heart... Agent: Lucas & Mercanti, LLP

20080161396 - Method of control of arthropod pests of game and pet birds: Ticks and other arthropod ectoparasitic pests of birds may be effectively controlled and the populations of ticks on treated birds significantly reduced by affixing to the bird a leg band or wing tag containing a pesticide in an amount effective against the tick or other pest.... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20080161397 - Composition for repelling mosquitoes: The present invention relates to a mosquito repellent comprises at least one or more mosquito repelling compound selected from the group consisting of citronellic acid, geranic acid and derivatives thereof in an effective amount to repel mosquitoes.... Agent: Sheldon Mak Rose & Anderson Pc

20080161399 - Agent for reduction of oxidized albumin level: The present invention provides a pharmaceutical agent and the like that decreases the level of oxidized albumin. Specifically, the present invention provides an agent for decreasing oxidized albumin, which contains at least one kind of branched-chain amino acid selected from isoleucine, leucine and valine.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080161398 - Stimulation of in vivo production of proteins: The invention relates to a formulation in the form of a pharmaceutical composition, a food product, a feed product or a dietary supplement, comprising leucine and protein in specific amounts. Consumption of a formulation according to the invention has a very positive effect on the generation of muscle tissue and... Agent: Banner & Witcoff, Ltd.

20080161400 - Use of forms of propofol for treating diseases associated with oxidative stress: Methods of treating diseases associated with oxidative stress such as metabolic diseases, cardiovascular diseases, neurological diseases, liver diseases, and pulmonary diseases in a patient comprising orally administering a therapeutically effective amount of forms of propofol that provide a high oral bioavailability of propofol are disclosed.... Agent: Timothy A. Worrall, Ph.d., J.d. Dorsey & Whitney LLP

20080161401 - Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors: This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S(═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent;... Agent: Nixon & Vanderhye, Pc

20080161402 - Targeting the reverse mode of the na+/ca2+ exchanger for the treatment of neurodegenerative conditions: A method for treating a neurodegenerative condition, in an animal of the mammalian species, including humans, comprising the step of administering to ganglion cells and their axons (optic nerve) of said mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having activity for blocking a... Agent: Allergan, Inc.

20080161403 - 1-(1,2 diphenyl-ethyl)-3-(2-hydroxyethyl)-thiourea compounds for combating animal pests: The present invention relates to a method of combating animal pests which comprises contacting the animal pest, their habit, breeding ground, food supply, plant, seed, soil, area, material or environment in which the animal pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to... Agent: Hutchison Law Group Pllc

20080161404 - Bicalutamide for delivering increasing steady state plasma levels: The present invention relates to a method of treating a metastatic prostate cancer patient by administering to said patient an effective amount of a bicalutamide (4′-cyano-α′,α′,α′-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide) containing formulation capable of delivering at least a mean steady state plasma level of (R)-bicalutamide enantiomer of 40 μg/ml; and to bicalutamide containing products... Agent: Astrazeneca R&d Boston

20080161405 - Biguanide composition and method of treatment and prevention of infections: The present invention includes a package for a medicament for treating infectious disease. The package comprises a first vessel and a second vessel. The first vessel contains a solid mixture of a biguanide antimicrobial agent and a polyol. The polyol has a melting point above room temperature. The ratio of... Agent: Bausch & Lomb Incorporated

20080161406 - Novel formulations of alpha-2,4-disulfophenyl-n-tert-butylnitrone: Novel pharmaceutical formulations of α-(2,4-disulfophenyl)-N-tert-butylnitrone and pharmaceutically acceptable salts thereof and the use of such formulations in the treatment of various diseases and conditions, especially stroke, are disclosed.... Agent: Klauber & Jackson

20080161407 - Methods for treating metabolic syndrome: v

20080161408 - Crystalline solid rasagiline base: The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.... Agent: Cooper & Dunham, LLP

20080161409 - Compositions for treatement of croup and methods of administering same: The invention relates to a racemic epinephrine inhalation solution, system, kit, and method for the treatment of croup. In particular, the racemic epinephrine solution is premixed, sterile, premeasured single unit dose of racemic epinephrine for the treatment of croup. More particularly, the racemic inhalation solution is free of antimicrobial preservatives... Agent: Mcguirewoods, LLP

20080161410 - Aminoalkanol derivatives: e

20080161411 - Methods and compositions for treating pulmonary disorders using optically pure (r,r)-formoterol: A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, a low incidence of the development of tolerance and an increased duration of action, as compared to racemic formoterol.... Agent: Heslin Rothenberg Farley & Mesiti P.c.

20080161412 - Process for preparation of sertraline hydrochloride form i: Provided is a process for preparation of sertraline HCl Form I on an industrial scale.... Agent: Kenyon & Kenyon LLP

20080161413 - Agent for increasing adiponectin in blood: Novel, safe, and highly effective agents for increasing adiponectin in blood that contain astaxanthin and/or an ester thereof as an active component are provided. Due to an increase in the amount of adiponectin in blood, the action of adipocytokine such as TNFα can be decreased, or the action of biologically... Agent: Mcleland Patent Law Office, P.l.l.c.

20080161414 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.... Agent: Scott A. Whitaker, Ph.d., J.d., Senior Intellecual Property Counsel

20080161415 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.... Agent: Scott A. Whitaker, Ph.d., J.d., Senior Intellecual Property Counsel

20080161416 - Compounds and methods for reducing undesired toxicity of chemotherapeutic agents: Novel compositions and formulations are disclosed that have use as toxicity-reducing agents for various chemotherapeutic agents and as treatment for certain diseases and conditions. The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.... Agent: Scott A. Whitaker, Ph.d., J.d. Senior Intellecual Property Counsel

20080161417 - Xylitol granules capable of directly being compressible into tablets and preparation process thereof: The present invention provides a xylitol granule directly compressible into tablet mainly comprising xylitol and polyvinyl pyrrolidone, and a process for preparing the same, and the granule may comprise sorbitol and hydroxypropylmethyl cellulose etc.... Agent: Kenyon & Kenyon LLP

20080161418 - Emollients and cosmetic compositons based on specific branched hydrocarbons: A cosmetic or pharmaceutical composition is provided. The composition contains a mixture of oils prepared by Kolbe electrolysis of branched chain fatty acids and mixtures of branched chain fatty acids with straight chain fatty acids. The fatty acids containing from 3 to 26 carbon atoms. The oils are a mixture... Agent: Cognis Corporation Patent Department

20080161424 - Compositions and methods for the systemic treatment of arthritis: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.... Agent: Chalker Flores, LLP

20080161420 - Method for monitoring disease progression or recurrence: The invention provides methods for detecting and monitoring diseases associated with genetic abnormalities in a subject.... Agent: Goodwin Procter LLP Patent Administrator

20080161422 - Methods and compositions for the treatment of lipid-associated disorders: The invention provides a method of identifying a niacin receptor modulator with reduced flushing effect compared to niacin or a niacin analog, comprising determining the MAP kinase activity of said modulator, wherein a decrease in MAP kinase activity induced by said modulator compared to MAP kinase activity induced by niacin... Agent: Fish & Richardson P.c.

20080161423 - Organ function maintaining or amelorating solution: The present invention relates to an organ function maintaining or ameliorating solution for maintaining or ameliorating the functions of an organ provided for organ transplantation, comprising a pharmacologically active substance comprising glycyrrhizic acid, glycyrrhetinic acid or a pharmacologically acceptable salt or derivative thereof in an organ preservation solution. The present... Agent: Birch Stewart Kolasch & Birch

20080161426 - P53 inhibitors and therapeutic use of the same: The therapeutic use of temporary p53 inhibitors in the treatment of p53-mediated diseases, conditions, and injuries is disclosed.... Agent: Marshall, Gerstein & Borun LLP

20080161419 - Prophylactic antimigraine agents: Since these prophylactic antimigraine agents show an excellent pharmacological effect in comparison with the cases in which a 5-HT2B receptor antagonist having a selective binding affinity to the 5-HT2B receptor or a 5-HT7 receptor antagonist having a selective binding affinity to the 5-HT7 receptor is used alone, they are useful... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080161425 - Regulation of tissue factor activity by protein s and tissue factor pathway inhibitor: The present invention relates to methods for the identification of compounds that increase or decrease the inhibitory effect of TFPI on tissue factor activity and/or Factor Xa activity and/or thrombin formation. The invention also relates to methods for the identification of compounds that increase or decrease the co-factor activity of... Agent: Kalow & Springut LLP

20080161421 - Tcell mediator/modulator assay based upon tcell restricted transgenic mouse: An in vivo screening assay for identifying an agent that interferes with T cell activation and/or -differentiation and/or modulation of other inflammatory effector cells.... Agent: Novartis Institutes For Biomedical Research, Inc.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.52892 seconds

PATENT INFO